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Optimization of Anti-Abeta Antibody Therapy 
Rachel Anne Karlnoski 
ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia, a 
disease that gradually destroys brain cells and leads to progressive decline in 
mental function. The presence of high densities of neuritic plaques composed of 
Aß in the cerebral cortices is a criterion for the post-mortem diagnosis of AD. The 
view that Aß deposition drives the pathogenesis of AD (amyloid hypothesis) has 
received support from a wide range of molecular, genetic, and animal studies. 
This hypothesis has been the focus of therapeutic intervention leading to the 
development of anti-Aß immunotherapy as a potential treatment. There is a great 
deal of evidence that supports the capacity of immunization against Aß to reduce 
amyloid pathology and restore memory function in transgenic mouse models of 
amyloidogenesis.  However, as a result of anti-Aß immunotherapy, many 
investigators have reported increased severity of cerebral amyloid angiopathy 
(CAA) and increased incidences of microhemorrhage. 
 The mechanism/s responsible for the redistribution of Aß to the 
vasculature is unclear. We examine two possible mechanisms that may influence 
the severity of CAA following immunization; the rate of Aß clearance with 
deglycosylated antibodies via a dose response study and anti-Aß antibody 
epitope specificity. Dose response results with a deglycosylated antibody showed 
 vi
that lower doses resulted in greater clearance of amyloid and significant 
improvements in cognition, suggesting that clearance mechanisms become 
saturated with high doses of antibody.  Treatment with antibodies directed 
against different epitopes of Aß implied that the degree of parenchymal Aß 
clearance determines the extent of vascular Aß accumulation; epitope specificity 
is not critical in directing the vascular accumulation. 
 Passive anti-Aß immunization can prevent Aß deposition in APP 
transgenic mice.  We investigated amyloid accumulation after immunization was 
terminated, and discovered that after treatment, amyloid began to accumulate as 
a factor of time and gradually built up but never reached the Aß levels in control 
APP mice. These data suggest that delayed deposition of amyloid leads to long 
term delays in AD associated pathology. These data strongly support the use of 
prophylactic immunotherapy treatments, and it appears that existing amyloid 
deposits will require interventions that actively clear amyloid as the only means to 
efficiently reduce brain Aß in AD. 
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INTRODUCTION 
Alzheimer’s disease: 
Alzheimer’s disease (AD) is the most common form of senile dementia.  
AD is characterized clinically by progressive cognitive decline and pathologically 
by amyloid plaques, neurofibrillary tangles, and neuron loss (Hardy and Selkoe 
2002). The cause of AD is unknown, however, 1-2% of AD patients genetically 
inherit the disease through autosomal-dominant inheritance. This type of 
inherited AD is termed familial AD (FAD) and results from a mutation on the 
amyloid precursor protein (APP), presenilin 1 (PS-1) or the presenilin 2 genes 
(PS-2).  It is now clear that mutations in these genes result in APP processing 
changes.  A common result of  mutations is a shift from a production of Aß that is 
40 amino acids long (Aß40) to Aß that is 42 amino acids long (Aß42).   These 
findings support the dominant hypothesis for the cause of AD, the Amyloid 
cascade hypothesis; a hypothesis that proposes that Aß accumulation is the 
cause of AD pathogenesis.  
APP structure, function, and metabolism 
           Amyloid precursor proteins are single transmembrane domain 
glycoproteins that span the membranes of several cell types.  The APP gene 
encompasses ~400 kb of DNA, contains 19 exons, and encodes several 
alternatively spliced APP mRNAs (Price et al 1998). Despite intensive study, the 
functions of APP have yet to be defined.  Some believe that the APP protein 
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maintains synaptic integrity and aids in neurite outgrowth. APP undergoes 
metabolism by secretase enzymes that cleave the protein endoproteolytically.  
APP metabolism by α-secretases results in the release of the large soluble 
ectodomain fragment (α-APPs) into the extracellular space and retention of an 
83-amino acid carboxyl-terminal fragment (CTF) in the membrane.  Alternatively, 
APP molecules can also be cleaved by ß-secretase.  ß-secretase cleavages 
generate a slightly smaller ectodomain derivative (ß-APPs) and retain a 99-
residue CTF in the membrane (Selkoe 1998).  Following a ß-secretase cleavage, 
a subsequent γ-secretase cleavage leads to the formation and release of Aß into 
the extracellular space.  Approximately 90% of secreted Aß peptides are Aß40, a 
soluble form of the peptide, whereas 10% of secreted Aß peptides are Aß42.  
Aß42 is highly fibrillogenic, readily aggregated, and deposited early and 
selectively in amyloid plaques (Price et al 1998). Aß42 has the ability to recruit or 
trap Aß40 into fibril-rich amyloid plaques. Diffuse plaques are largely comprised 
of Aß42, with little or no Aß40 immunoreactivity (Iwatsubo et al 1994). Aß40 
accumulates in the vasculature and causes a condition known as cerebral 
amyloid angiopathy (CAA).  
            The first specific genetic cause of AD to be identified was missense 
mutations in APP by Goate et al 1991.  These mutations result in FAD, which 
encompass only 1-2% of all AD cases.  The mutations are located within 
proximity to the cleavage sites.  This discovery suggests that these mutations 
lead to AD by altering proteolytic processing at the three secretase cleavage 
sites.  Cells that express the APP mutation do not appear to secrete higher levels 
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of Aß (other than the Swedish mutation) but, rather, secrete a higher fraction of 
Aß42 relative to cells that express wild-type APP (Suzuki et al 1994). 
Presenilin structure, function, and metabolism 
            PS1 and PS2 are highly homologous proteins that have six to nine 
transmembrane domains found in the intracellular membranes of rough 
endoplasmic reticulum and Golgi apparatus.  The N- and C-termini are oriented 
toward the cytoplasm (Doan et al 1996). The functional roles of presenilins are 
not fully understood.  However, studies have shown that presenilins play a role in 
intracellular protein trafficking, including components of γ-secretase, and are 
required for the γ-secretase cleavage. Presenilins are also required for Notch 
cleavage, which is involved in developmental signaling. PS1 knockout mice show 
developmental abnormalities similar to those seen in mice with components of 
the Notch system knocked out (Wong et al 1997).  Like APP, presenilins are 
processed and cleaved to produce an N- and C-terminal fragment. It is not clear 
whether the holoprotein or the protein fragments are important physiologically or 
pathologically.  
 While the mutations found in the amyloid precursor protein are with in the 
vicinity of cleavage sites, mutations in presenilin are found throughout the 
protein.  Mutations in the presenilin protein result in a subtle alteration of APP 
processing causing an increased production of Aß42 over Aß40.  Over 50 
mutations in the presenilin proteins have been found to cause FAD (Scheuner et 
al., 1996).   
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 In summary, the two known genetic causes of AD are mutations in the 
APP and PS proteins.  Mutations in these proteins all cause an increase in the 
production of Aß42, the longer, more hydrophobic form of Aß.  These genetic 
data strongly support the “Amyloid cascade hypothesis”; the dominant hypothesis 
that proposes that an increased accumulation of Aß42 initiates the pathogenic 
events in AD. Aß42 accumulates and aggregates, disrupts synapse function, 
activates microglia and astrocytes which release cytokines and reactive oxygen 
species, further enhances neuritic injury, alters ionic homeostasis, alters kinase 
and phosphatase activities, causes the formation of neurofibrillary tangles, and 
ultimately widespread neuronal dysfunction and cell death (Hardy et al 2002).   
 
Transgenic Models of Aß Amyloidogenesis:  
 A major advance in AD research has been made in the last several years 
with the generation of mice that develop age-dependent Aß accumulation and 
deposition in their brain and age-dependent learning deficits.  The first transgenic 
model to show numerous extracellular amyloid deposits were the PDAPP or 
APPV717F mice produced by Games and colleagues in 1995 (Games et al 1995).  
The PDAPP mice were generated using a human APP minigene encoding the 
APP717VÆF mutation; driven by a platelet derived growth factor, PDGF-ß, 
promoter.  These mice were hemizygous for the transgene and exhibited 
deposits of human Aß at 6-9 months of age.  Similar to the pathology found in 
human AD, these mice deposited amyloid in the hippocampus, corpus callosum, 
and cerebral cortex.  Age-dependent increases in amyloid deposit size and 
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density were observed.  GFAP-positive reactive astrocytes, activated microglia, 
and distorted neurites were closely associated with the Aß plaques.  PDAPP 
mice also exhibited progressive decline in cognitive function when tested with the 
water-maze, a behavioral paradigm for learning and memory.  This cognitive 
decline and inability to recall platform locations correlated with age-related 
increases in amyloid plaque density in the hippocampus (Chen G. et al 2000).   A 
transgenic model with similar phenotypic findings was reported by Hsiao et al 
(Hsiao et al 1996) and contained a double mutation K670N and M671L in the 
human APP gene under the control of a hamster prion promoter (PrP).  This 
double mutation is also known as the Swedish mutation because it was found in 
a large Swedish family with early onset FAD.  Transgenic mice with the Swedish 
mutation are referred to as Tg2576 or APPSW  mice.  Similar to the PDAPP mice, 
the Tg2576 mice showed behavioral impairments in learning and memory that 
correlated with increased amounts of Aß (Hsiao et al., 1996). They also showed 
amyloid deposits surrounded by GFAP-immunoreactive astrocytes and 
dystrophic neurites in the cerebral cortex and hippocampus.  TgCRND8 mice 
encode V717F and the KM670/671NL mutation under the control of the PrP gene 
promoter (Chishti et al 2001).  These mice have robust dense-cored plaques and 
neuritic pathology by 3 months of age, along with learning impairments that were 
correlated with Aß42 levels in a reference memory version of the Morris water 
maze (Janus et al 2000).   
 PDAPP and Tg2576 mice have been crossed with other genetically 
modified mice. One of these was the presenilin-1 (PS1) mouse from Duff and 
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colleagues (Duff et al 1996).  The crossing of Tg2576 with a mutant PS1M146L 
transgenic line generated a transgenic model with accelerated amyloid 
deposition in the cerebral cortex and hippocampus far earlier than the singly 
transgenic Tg2576 mice (Holcomb et al 1998).  In these doubly transgenic mice, 
the diffuse deposits were primarily composed of Aß42 while the compact plaques 
and vascular Aß are composed of Aß40. GFAP reactive astrocytes, dystrophic 
neurites and activated microglia were more pronounced in the doubly transgenic 
mice compare to the singly transgenic Tg2576 or PS1 mutant mice (Gordon MN 
et al 2002). The doubly transgenic mice showed  increased activity in the Y-maze 
test having significantly higher total number of arm entries than the Tg2576 or 
PS1 mutant mice (Holcomb et al 1998).  Follow-up studies showed that the 
doubly transgenic mice were significantly impaired at 9 months of age compared 
to non-transgenic mice in the Y-maze test (Holcomb et al 1999).   
 The main objective in using transgenic models of amyloidogenesis is to 
provide insight into the role of Aß in Alzheimer’s disease.  Memory dysfunction is 
a very consistent behavioral finding in APP mutant mice.  Correlations with 
cognitive decline and age-related increases in amyloid plaque density suggest 
that amyloid plays an underlying role in memory impairment.   It is important to 
note that these models are not “complete” models of AD in that they do not 
develop marked neuronal loss or typical neurofibrillary tangles found consistently 
in human AD. However, the patterns of deposition, regional distribution, and even 
the anatomical localization of the short and long variants of Aß mimic the human 
disease (Morgan 2003). For this reason, our group and several others are 
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focusing on finding therapeutic approaches to reduce Aß loads and reverse 
cognitive decline in transgenic models of amyloid deposition.     
 
Immunotherapy for AD: 
Monoclonal antibodies (mAbs) were first shown to inhibit the aggregation 
of fibrillar Aß in an in vitro study by Solomon and colleagues in 1996 (Solomon et 
al 1996).   In this study mAbs were raised against “aggregating epitopes” of Aß; 
specifically amino acids 1-28 and 8-17.  These epitopes were found to be sites 
where Aß aggregation was initiated.  The mAb 1-28 showed the ability to prevent 
Aß aggregation and convert fibrillar Aß to a nonfibrillar conformation. However, 
these changes were not exhibited by the mAb 8-17.  In the following year, 
Solomon and colleagues showed that mAb raised against the N-terminal region 
of Aß, amino acids 1-16, caused disaggregation of fibrils, restoration of Aß 
solubility, and inhibition of Aß neurotoxicity on PC 12 cells at molar ratios ranging 
from 10 to 100 Aß/mAb (Solomon et al 1997).  It was also found that mAb which 
bind to epitopes 13-28 and the C-terminal region of Aß were considerably less 
effective.  
Immunizations against Aß in transgenic models of AD were first 
demonstrated by Schenk and colleagues in 1999 using the PDAPP mouse 
(Schenk et al 1999). In this study 2 groups of mice, young (6 weeks) and old (11 
months) were treated with immunogens that were either synthetic Aß42 or 
peptides derived from the primary amino acid sequence of serum amyloid-P 
component (SAP).  Two additional groups were either left untreated or were 
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immunized with PBS as controls.  Similar titer responses against Aß42 were 
seen in the older and younger animals. The Aß42 peptide vaccine was shown to 
prevent Aß deposition in the young mice and cause a near-total reduction of Aß 
in the older mice. The Aß reduction was accompanied by a virtual elimination of 
dystrophic neurites and astrogliosis.  In contrast, the SAP peptide vaccination did 
not show significant reductions in Aß compared to control mice.  It can be 
concluded from this study that active Aß42 immunization either prevents 
deposition and/or enhances the clearance of Aß from the brains of PDAPP mice.  
One suggested method of clearance was that anti-Aß antibodies triggered 
microglial cells to clear Aß using signals mediated by Fc receptors.  This was 
postulated because Aß-immunoreactive microglial cells appeared in regions of 
remaining plaques.   
 Bard et al (Bard et al 2000) further tested the postulate that Aß clearance 
was mediated by microglial phagocytosis in a passive immunization study. 
PDAPP mice were injected intraperitoneally, weekly for 6 months with anti-Aß 
mAbs.   Peripherally administered mAbs were found to enter the CNS, decorate 
plaques, and induce clearance of preexisting amyloid.  Unlike actively immunized 
mice, mice receiving exogenous mAbs (passively immunized) did not 
demonstrate a T-cell response to Aß.  This indicates that a T-cell response is not 
necessary for Aß clearance in PDAPP mice. An ex vivo assay using microglial 
cells cultured with unfixed sections of either PDAPP mouse or human AD brains 
was established to examine the effect of antibodies on plaque clearance.  
Monoclonal antibodies that effectively reduced amyloid in the in vivo studies also 
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reduced amyloid deposits in the ex vivo assays.  Following mAb treatment in the 
ex vivo assay, nearly all amyloid was contained in vesicles within the exogenous 
microglial cells.  F(ab)2 fragments of an effective mAb were prepared to 
determine if Fc receptors were necessary for Aß phagocytosis.  F(ab)2 fragments 
are antibodies with intact antigen binding regions but lack the Fc region required 
for FcγR activation.  F(ab) 2  fragments failed to trigger microglial phagocytosis, 
indicating that clearance of Aß was Fc receptor-mediated.  Wilcock et al (2001) 
found that APP+PS1 mice actively inoculated 5 times with Aß1-42 showed a 
correlation between increased microglial activation and fibrillar Aß reductions in 
the hippocampus (Wilcock et al 2001).  Our group further demonstrated the role 
of microglia in Aß clearance by intracranially administering mAbs followed by the 
administration of anti-inflammatory drugs to impair the microglial response.  The 
impairment of microglia resulted in a complete arrest of anti-Aß antibody-
mediated clearance of fibrillar Aß in the hippocampus (Wilcock et al 2004).  In a 
second series of studies, anti-Aß F(ab)2 fragments were intracranially 
administered to APP+PS1 mice.  As previously shown by Bard and colleagues in 
an ex vivo study, the anti-Aß F(ab)2  were also less effective at activating 
microglia and therefore less effective at removing fibrillar Aß in vivo; although 
diffuse Aß was reduced.  On the contrary, topical application of N-terminal F(ab)2   
fragments and full length N-terminal antibodies showed similar reductions in 
diffuse Aß and dense-core deposits after 3 days in Tg2576 and PDAPP mice 
indicating that non-Fc mediated mechanisms are also involved in the clearance 
of Aß (Bacskai et al., 2002). 
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Although active and passive immunization were shown to reduce amyloid 
burden and reverse dystrophic neurites in vivo, the effects of vaccination caused 
microglial activation and inflammation.  Morgan and colleagues proposed that 
inflammatory reactions caused by the vaccine might disrupt normal memory 
function and tested this theory in APP+PS1 transgenic mice that were actively 
vaccinated for 5 months (Morgan et al 2000).   The results were, in fact, 
completely opposite from what they had expected.  Eleven to twelve month old 
APP+PS1 mice vaccinated with Aß performed equivalently with nontransgenic 
mice in the radial arm water maze (RAWM) test of working memory.  This 
indicated that microglial activation caused by vaccination was insufficient to 
disrupt learning and memory functions.  Vaccinations were continued until the 
mice were 15-16 months old and were retested in the RAWM.  At this age the Aß 
vaccinated mice were slower to learn the platform locations than the non-
transgenic mice, however, by trial 5 the Aß vaccinated transgenic mice and non-
transgenic mice were virtually indistinguishable. Control transgenic mice were 
memory deficient. In another behavioral study, TgCRND8 mice were vaccinated 
with Aß42 or islet-associated polypeptide (IAPP), a peptide with similar 
biophysical properties to Aß but not associated with the CNS (Janus et al 2000).  
Sera from Aß42 immunized mice stained fibrillar Aß, and very weakly stained 
diffuse, non-fibrillar Aß deposits.  This indicated that the Aß42 antibody used in 
this study was directed toward Aß in a ß-pleated sheet conformation.  The mice 
were also tested in a reference memory version of the Morris water maze test.  A 
series of reversal tests confirmed that Aß-immunized TgCRND8 mice had 
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improved performance.  Aß42 immunization caused ~50% reduction in number 
and size of amyloid plaques without changing the levels of APP metabolism, 
measured by amino-terminal (ßAPPs) or carboxy-terminal (CTFs) secreted 
fragments in the brain.   
Three mechanisms of action have been presented for the removal of 
amyloid deposits following active or passive immunization.  The first involves the 
catalytic disaggregation of Aß into fibrils leading to monomeric Aß and clearance 
from the brain (Solomon et al 1997).  Microglial mediated phagocytosis of Aß is 
the second proposed mechanism of action and is supported by several 
investigators (Schenk et al., 2002),  (Bard et al., 2000), (Wilcock et al.,2004).   
The third mechanism of action was proposed when mAbs directed against the 
central domain of Aß were peripherally administered to 3 month old PDAPP 
mice, resulting in a rapid 1000 fold increase in plasma Aß and reductions in 
amyloid burden in the brain without the mAb actually entering the brain.  It is 
thought that the antibody sequestered plasma Aß which disrupted the equilibrium 
of Aß in the CNS and plasma, and  caused an efflux of Aß out of the brain into 
the periphery (DeMattos et al 2001).   
Human Vaccine Trials 
After discovering that antibodies against Aß could reduce AD pathology 
and improve cognition in APP mouse models, Elan Pharmaceuticals and Wyeth 
Laboratories initiated clinical testing with preaggregated, fibrillar, synthetic Aß1-
42 under the name of AN 1792. The single and multiple dose Phase I trials 
showed that AN 1792 was well tolerated and a good immunological response 
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was obtained (Bayer et al., 2005).  In the Phase IIa study, 372 patients with mild 
to moderate AD were enrolled, 300 of which received AN 1792 plus QS-21 
adjuvant intramuscularly, and 72 patients received a saline injection (Gilman et 
al.,2005).  Unfortunately, signs and symptoms consistent with 
meningoencephalitis were reported in 18 of the patients treated with the active 
vaccine (Orgogozo et al 2003).   As a result, all study dosing was halted in 
January 2002. Although dosing was terminated, the study remained intact and 
was adjusted to monitor the patients in a blinded fashion. Biological and long-
term clinical follow-up revealed indications for efficacy and proof of concept- even 
after the occurrence of meningoencephalitis.  
 The cognitive status of phase IIa patients continued to be monitored 
following the cessation of the trial. Hock and colleagues reported that patients 
who generated plaque reactive antibodies against Aß remained cognitively stable 
while those who did not generate such antibodies worsened when tested with the 
Mini Mental State Examination (Hock et al 2003). One patient in the Phase I trials 
that received the AN-1792 vaccine died from a pulmonary embolism 20 months 
after the first injection and 12 months after the last injection (Nicoll et al 2003). 
The patient’s brain, examined post-mortemly, strongly resembled the changes 
seen in transgenic mice that received Aß immunotherapy.  Focal reductions in 
cortical amyloid plaques, dystrophic neurites and astrocytosis along with Aß-
immunoreactive microglia were seen. There were also signs of CNS infiltration by 
CD4+ T-cells, suggesting an inflammatory and autoimmune reaction. Aß 
immunostained aggregates were found in proximity to phagocytic microglia, 
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suggesting the microglial mediated mechanism of Aß clearance. Two additional 
case reports were published that showed similar pathological findings in patients 
treated with AN-1792 with the addition of multiple small hemorrhages and 
increased CAA (Ferrer et al 2004).  One patient was immunized with 3 injections 
of AN-1792 and did not exhibit symptoms of encephalitis.  Similar to the first 
patient, this patient’s post mortem examination showed an almost complete 
absence of amyloid and neuritic plaques in the cortex.  In fact, Aß-
immunoreactivity was only found in aggregates within CD-68-immunoreactive 
microglia. Interestingly, only a minimal amount of lymphocytic infiltration was 
observed (Masliah et al 2005).   
Although the clinical trials with AN 1792 were halted, the study yielded 
several very important insights into the clinical potential of immunization for AD.  
Neuropathological investigations of 4 patients immunized with AN-1792 showed 
reduced ß-amyloid pathology in certain brain regions, where tau pathology 
remained (Bombois et al., 2007),  (Nicoll et al., 2003), (Ferrer et al., 2004), 
Masliah et al,.2005).  Importantly, amyloid reductions were observed in the 
presence and absence of meningoencephalitis, suggesting that T cell infiltration 
was not required for ß-amyloid removal.  Despite preserved tau pathology, 
measurements of tau in CSF samples showed decreased tau levels, trending 
towards values seen in normal elderly subjects, thus reinforcing the critical role of 
Aß in AD pathology (Gilman et al., 2005). In addition to reductions in AD 
pathology, patients which generated high antibody titers as per the tissue 
amyloid plaque immunoreactivity assay (TAPIR) showed cognitive improvements 
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or slower rates of decline in activities of daily living (Hock et al., 2003). T-cell 
infiltration was confirmed in post mortem exams, along with an increased 
incidence of microhemorrhage and CAA.  These adverse effects can hopefully be 
overcome with passive immunization.    
In order to overcome the adverse effects seen with active immunization, 
many studies have been conducted using passive immunization with monoclonal 
anti-Aß antibodies. Passive immunization has several advantages over active 
immunization. The first advantage is that passively administered antibodies are 
not expected to elicit a T-cell response. Another advantage of passive 
immunization is control of the dosage of antibody in circulation.  Antibody 
production resulting from active vaccination requires the activation of B-cells by T 
helper cells.  In the elderly however, this interaction is impaired and there is an 
age-related increase in the number of non-responders to vaccination (Murasko et 
al., 2002).  In a small subset of patients treated with AN 1792, 12 out of 24 
showed relatively low serum titres (<1:1000), while 4/24 had very high titres 
(>1:10,000) (Hock et al., 2002).  Passive immunization allows for the 
administration of a measurable and controllable amount of antibody; and 
overcomes the hurdles of hyporesponsiveness and variablity. Thus, inadequate 
immune responses or potential adverse reactions can be controlled.  The dosage 
and frequency of administration of passive immunotherapy can be adjusted to 
suit the situation.  Another advantage is that antibodies raised against specific 
epitopes on Aß can be generated and compared for efficacy (Morgan and Gitter 
2004).   
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Cerebral Amyloid Angiopathy: 
Cerebral amyloid angiopathy (CAA) is the deposition of amyloid in the 
walls of medium and small sized leptomeningeal and cortical arteries. Severe 
CAA may be associated with micro aneurysm formation, fibrinoid necrosis, or 
microangiopathies (Rensink et al 2003).  Increases in CAA have been found as a 
consequence of both active and passive immunization.  Passively immunized 
APP23 mice with an N-terminal mAb showed significant reductions in amyloid 
load while the frequency of CAA-associated cerebral hemorrhages was 
increased more than two-fold (Pfeifer et al 2002).  Similar findings were reported 
by Wilcock and colleagues when Tg2576 mice were passively immunized with a 
C-terminal mAb. This study also evaluated behavior and found that despite the 
increased CAA and microhemorrhages, Tg2576 mice still showed cognitive 
improvements following passive immunization (Wilcock et al 2004b).   Two out of 
the three post-mortem brains of patients treated with AN-1792 showed CAA and 
multiple small microhemorrhages remaining after treatment despite the removal 
of plaques (Nicoll et al 2003; Ferrer et al 2004; Masliah et al.,2005).    
A possibility for increased CAA is that immunization may stimulate the 
efflux of Aß from the brain through perivascular drainage pathways (Nicoll et al 
2003).  Another possibility is that amyloid clearance may disrupt the integrity of 
the blood brain barrier and blood vessels by removing amyloid associated with 
the vessels (Orgogozo et al 2003).  Aß-containing blood vessels are commonly 
surrounded by inflammatory activity (activated microglia); raising the possibility 
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that inflammation may induce abnormalities in blood vessel function (Greenberg 
2003).  Passive immunization already avoids the T-cell activation otherwise 
caused by active immunization.  However, immunohistochemical measures of 
microglial activation have shown significant increases in CD45 and Fcγ receptors 
II and III (CD16b and CD32) in areas of amyloid deposition after 1 and 2 months 
of passive immunization (Wilcock et al 2004b). CD45 positive microglia were 
found closely associated with amyloid burdened blood vessels (Wilcock et al 
2004a).   
In order to overcome the binding of the Fcγ receptor to the antigen-
antibody complex, deglycosylated Aß antibodies were produced by Rinat 
Neurosciences Corporation.  Deglycosylation of an antibody removes the 
carbohydrate side chains on the Fc portion of the antibody and significantly 
impairs low affinity Fcγ receptor recognition. Low affinity Fcγ receptors, mFcγIIb 
and mFcγIIIa, are the majority of Fcγ receptors in mice (Ravetch 1997; Gessner 
et al., 1998).  Also impaired is the antibody Fc portion’s ability to bind 
complement (Windelhalke et al, 1980).   
Deglycosylated anti-Aß antibodies were injected into the hippocampi and 
cortices of Tg2576 mice and were found to reduce diffuse and fibrillar Aß as 
efficiently as the intact mAb in both regions without increasing Fcγ expression or 
CD45 expression (Carty et al 2006). Intraperitoneal administration of the 
deglycosylated antibody into Tg2576 mice for 4 months showed similar results to 
the intact antibody in that diffuse and fibrillar Aß was reduced, and cognitive 
improvements were observed when tested in the RAWM.  CAA was increased 
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3.5-fold in the frontal cortex and 3-fold in the hippocampus in mice that received 
the intact antibody. In comparison, mice treated with the deglycosylated antibody 
showed significantly less vascular amyloid than the mice treated with the intact 
antibody; 2-fold in the frontal cortex and 1.5-fold in the hippocampus when 
compared to the mice administered the control antibodies. The incidence of 
microhemorrhage in the deglycosylated treated mice was 67% less than that 
found in the intact treated mice (Wilcock et al., 2006). These data suggest that 
the deglycosylated antibody uses a different method of Aß removal than the 
intact antibody.  It is strongly suggested that intact antibodies eliminate Aß 
through a microglial mediated phagocytosis, which requires Fc receptor 
recognition.  The deglycosylated antibody does not activate the Fc receptor on 
microglia yet still reduces Aß loads to a similar extent.  A proposed mechanism of 
deglycosylated antibody removal of Aß is the disaggregation of Aß into more 
soluble forms, a method of Aß removal that does not involve microglial activation.  
Alternatively, the deglycosylated antibody may cause Aß internalization by non-
FcR receptors, such as scavenger receptors (Brazil et al., 2000). Hartman and 
colleagues recently showed that treatment with an anti-Aß antibody was able 
rescue the Aß-induced inhibition of long term potentiation (LTP) in the CA1 
hippocampal region of PDAPP mice compared to untreated PDAPP mice which 
failed to induce LTP (Hartman et al., 2005).  Therefore, treatment with an anti-Aß 
antibody may be able to reverse functional abnormalities caused by Aß by 
changing the microenvironment at a transcriptional and translational level.  
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IgG isotypes and Fc-Gamma Receptors (FcγR) 
Biological and pathological activities differ with various IgG isotypes. 
These differences have conventionally been attributed to disparities in the ability 
of certain isotypes to engage complement or one of the known FcγR.  The finding 
that individual FcγRs interact differently with IgG isotypes in mediating protective 
inflammatory responses is certainly relevant for the potential use of these 
receptors as therapeutic targets in the treatment of disease.  Murine effector cells 
such as microglia within the CNS express four different classes of IgG-specific Fc 
receptors: a high affinity receptor, FcγRI, two low affinity receptors, FcγRII and 
FcγRIII, and an intermediate affinity receptor, FcγRIV (Ravetch et al., 1998) 
(Nimmerjahn et al., 2005).  Fcγ receptors I, III, and IV are all activating receptors 
characterized by an immunoreceptor tyrosine-based activation motif (ITAM).  
These receptors are important for triggering phagocytosis by activated 
macrophages.  FcγRII is an inhibitory receptor characterized by the presence of 
an ITIM motif that recruits inhibitory phosphatases that limit effective signaling.     
 Bard et al (2003) examined the efficacy of different IgG isotypes on plaque 
removal from PDAPP brain sections in an ex vivo and in vivo assay and found 
that IgG2a antibodies against Aß were more efficacious than IgG1 or IgG2b in 
reducing neuropathology.  IgG2a antibodies exhibit the highest affinity for FcγRI 
therefore the affinity of IgG for Fcγ receptors may be important in the efficiency of 
the antibody.  Chauhan et al 2005 found that all IgG1 antibodies, when 
administered in a single bolus ICV injection in TgCRND8 mice, cleared cerebral 
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amyloid more efficiently than IgG2a and IgG2b.  IgG1 has the highest affinity for 
FcγRIII.  FcγRIV was recently discovered and  found to have an intermediate 
binding affinity for IgG2a and IgG2b, a mechanism that can be proposed for the 
enhanced activity of IgG2 over IgG1 (Nimmerjahn et al., 2005). If microglial 
phagocytosis via the Fcγ receptor is responsible for not only removal of 
parenchymal amyloid but also for the increased CAA and microhemorrhage then 
it is possible that the IgG isotype of an antibody may result in more CAA and 
microhemorrhage. 
 However, conflicting data suggests that effective clearance of Aß by anti-
Aß antibodies can be obtained in the absence of Fc receptors. Das et al (2003) 
showed that when they actively immunized APP transgenic mice crossed with Fc 
receptor knockout mice (lack expression of FcγRIII and FcγRI) they showed the 
same amount of Aß reductions as immunized, age-matched APP transgenic 
mice. 
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ABSTRACT 
 
Anti-Aß antibody administration to amyloid depositing transgenic mice can 
reverse amyloid pathology and restore memory function. However, in old mice, 
these treatments also increase vascular leakage and promote formation of 
vascular amyloid deposits. Deglycosylated antibodies with reduced affinity for Fc-
γ receptors and complement are associated with reduced vascular amyloid and 
microhemorrhage, while retaining amyloid clearing and memory enhancing 
properties of native intact antibodies.  In the current experiment we investigated 
the effect of 3, 10, or 30 mg/kg of deglycosylated antibody (D-2H6) on amyloid 
pathology and cognitive behavior in old Tg2576 mice.  A control group received 
antibody against drosophila amnesiac protein (AMN) at a concentration of 
10mg/kg. All mice were given weekly intraperitoneal injections for 12 weeks.   
The 3 mg/kg dose of deglycosylated antibody effectively reversed learning 
and memory deficits and significantly reduced diffuse and compact plaque 
burden in these mice. In contrast, the 30 mg/kg dose failed to improve memory 
and minimally reduced plaque pathology. Interestingly, all groups had similar 
increases in CAA despite the differences in plaque clearance. The number of 
microhemorrhages was less than one profile per section for all groups, 
considerably less than found in prior studies with intact antibody. In conclusion, 
low doses of deglycosylated antibodies appear more efficacious than higher 
doses in reducing pathology and memory loss in APP transgenic mice. These 
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data suggest that excess antibody unbound to antigen can interfere with antibody 
mediated Aß clearance, possibly by saturating the FcRn antibody transporter.  
 
INTRODUCTION 
Passive immunization with anti-Aß antibodies has been shown to reduce 
Aß load and  reverse cognitive decline while increasing cerebral amyloid 
angiopathy (CAA) and microhemorrhage in transgenic models of amyloid 
deposition  (Wilcock et al., 2004) (Racke et al., 2005). Although the mechanism/s 
responsible for the redistribution of Aß is unclear, we have recently discovered 
that deglycosylation of the Fc portion on the anti-Aß antibody significantly 
reduces the severity of CAA and microhemorrhage compared to native 
antibodies when passively administered to Tg2576 mice, albeit with slightly lower 
clearance of parenchymal amyloid deposits (Wilcock et al., 2006) (Carty et al., 
2006).  
Fcγ receptor and complement activation are two important mechanisms 
that initiate phagocytosis by microglia and macrophages.  We and others have 
shown evidence for microglial involvement in the removal of amyloid using both 
intracranial and systemic administration of anti-Aß antibodies (Bacskai et al., 
2001) (Chauhan et al., 2004) (Wilcock et al., 2003) (Wilcock et al., 2004a) 
(Wilcock et al., 2004b) (Bard et al., 2000) (Bard et al., 2003). We have reported 
observations of reactive microglia surrounding blood vessels that are both highly 
burdened with Aß plaque and positive for microhemorrhage following passive 
immunization with anti-Aß antibodies. Following these observations, we 
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suggested that activated microglia bound opsonized amyloid and migrated to the 
vasculature to dispose of the material (Wilcock et al., 2004b). This evidence 
suggests that activated microglia may exacerbate the CAA and 
microhemorrhage.   
The deglycosylation of the carbohydrate side chains on the Fc portion of 
an anti-Aß antibody greatly reduces the affinity of the antibody for Fcγ receptors, 
particularly murine FcγRIIb and FcγRIIIa, on effector cells like microglia yet the 
antibodies are fully capable of binding to Aß in the same way as the intact 
antibody (Ravetch et al., 1997) (Gessner et al., 1998). Deglycosylation also 
impairs the antibody’s ability to bind complement (Winkelhake et al., 1980). 
Therefore, one explanation for our prior results is that by deglycosylating the Aß 
antibody, we are able to mitigate specific Aß clearance mechanisms that 
contribute to the accumulation of CAA and microhemorrhage.  An alternative, 
however, is that our prior observations were primarily due to a slower rate of Aß 
clearance, which, by avoiding saturation of normal vascular efflux pathways, 
minimized the accumulation of vascular deposits. One means of resolving the 
qualitative (specific mechanism) versus quantitative (slower removal) 
explanations of the effects of antibody deglycosylation on vascular amyloid 
accumulation would be to increase the rate of amyloid removal with 
deglycosylated antibodies. If a higher rate of amyloid removal by deglycosylated 
antibody increased vascular deposits like native antibodies, then the quantitative 
explanation would be the most likely explanation.  
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Here we examined the rate of Aß clearance from the brain by using 3 
doses of deglycosylated anti-Aß antibody in old Tg2576 mice.  Based on 
previous studies that have shown that 0.1% of peripherally administered antibody 
enters the CNS, we designed a dose response study using the deglycosylated 
Aß antibody with the notion that higher doses of peripherally administered 
antibody would enter the brain and clear amyloid at a higher rate, while the 
smallest dose would clear amyloid at the slowest rate (Banks et al., 2002) (Bard 
et al., 2000).  Somewhat paradoxically, we found that long term systemic 
administration of low doses of deglycosylated anti-Aß were more effective at 
reducing amyloid deposits and reversing cognitive deficits in old APP transgenic 
mice when compared to animals treated with intermediate and higher doses of 
antibody.  
 
MATERIALS AND METHODS 
Experimental Design. All APP Tg2576-derived (Hsiao et al., 1996) mice were 
bred in our facility at the University of South Florida and genotyped using 
previously described methods (Holcomb et al., 1998) (Gordon et al., 2002).  
Importantly, we have intentionally bred out the retinal degeneration 1 mutation 
from this colony to avoid the inclusion of occasional mice that are blind due to 
homozygous inheritance of this mutation contributed by the SJL/J background 
(Alamed et al., 2006). Twenty Tg2576 mice (19 months of age) were assigned to 
1 of 4 groups as follows; three groups received the deglycosylated antibody (D-
2H6 Aß33-40 IgG2b; Rinat Neurosciences, Palo Alto, CA) at 3 mg/kg, 10mg/kg, or 
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30mg/kg in saline vehicle.  The fourth group received a control IgG antibody 
against drosophila amnesiac protein (AMN) at a concentration of 10mg/kg 
(mouse monoclonal anti-drosophila amnesiac protein IgG2b; Rinat 
Neurosciences, Palo Alto, CA).  All mice were given weekly intraperitoneal 
injections of the appropriate antibody and dose for 12 weeks.  A fifth group of 
age- matched, nontransgenic mice were used as a control in the behavioral 
sector of the experiment.  
 
Deglycosylation of 2H6. A deglycosylated version of 2H6, D-2H6, was generated 
by enzymatic removal of N-linked glycans.  2H6 was incubated at 37°C for 1 
week with peptide-N-glycosidase F (QA-Bio, San Mateo, CA,  0.05 U/mg of 
antibody) in 20 mM Tris-HCl pH 8.0; 0.01% Tween. The deglycosylated antibody 
was purified by Protein A chromatography and endotoxin was removed by Q-
Sepharose. Completeness of deglycosylation was verified by MALDI-TOF-MS 
and protein gel electrophoresis (Carty et al., 2006).  
 
Behavioral Paradigm. Following 3 months of treatment the mice were subjected 
to a two day behavioral paradigm consisting of the radial-arm water maze 
paradigm (RAWM), followed by an open pool visible platform task. The radial arm 
water maze task was run as previously described (Wilcock et al., 2004). Briefly, 
the RAWM contained 6 arms radiating out of an open central area, with a hidden 
escape platform located at the end of one of the arms (Alamed et al., 2006). On 
day 1, 15 trials were run in 3 blocks. The start arm was varied for each trial, with 
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the goal arm remaining constant for both days. For the first 11 trials, the platform 
was alternately visible, then hidden, and then remained hidden for the last 4 
trials. On day two the testing was similar except that the platform was hidden 
for all trials. The number of errors (incorrect arm entries) was measured in a one 
minute time frame. Mice failing to make an arm choice in 15 seconds were 
assigned 1 error. In order to minimize the influence of individual trial variability, 
each mouse's errors for three consecutive trials were averaged producing 5 data 
points for each day which were analyzed statistically by ANOVA using StatView 
(SAS Institute Inc., NC). Next, the mice were run in a one day open pool task 
with a visible platform to test swimming ability and eyesight. Any mice 
demonstrating impaired ability to swim or to see were excluded from behavioral 
analyses.  
 
ELISA analysis of serum Aß. Serum was diluted and incubated in 96-well 
microtiter plates (MaxiSorp; Nunc, Rosklide, Denmark), which were precoated 
with antibody 6E10 (Biosource, Camarillo, CA) at 5 µg/ml in PBS buffer, pH 7.4. 
The detection antibody was biotinylated 4G8 (Signet, Dedham, MA) at a 1:5000 
dilution. Detection was done using a streptavidin-horseradish peroxidase 
conjugate (Amersham Biosciences, Arlington Heights, IL), followed by 
tetramethylbenzidine substrate (Sigma-Aldrich, St. Louis, MO). Standard curves 
of A 1-40 (American Peptide, Sunnyvale, CA) scaling from 6-400 pM were used. 
ELISA values for serum Aß levels and circulating antibody levels were analyzed 
using a one-way ANOVA followed by Fischer’s LSD means  
 27
 
ELISA analysis of serum anti-Aß antibodies: The anti-Aß antibody was 
dissociated from endogenous Aß in serum as described previously (Li et al., 
2004). Briefly, serum was diluted in dissociation buffer (0.2 M glycine HCl and 
1.5% BSA, pH 2.5) and incubated at room temperature for 20 min. The sera were 
pipetted into the sample reservoir of a Microcon centrifugal device (10,000 
molecular weight cutoff; YM-10; Millipore, Bedford, MA) and centrifuged at 8000g 
for 20 min. at room temperature. The sample reservoir was then separated from 
the flow-through, placed inverted into a second tube, and centrifuged at 1000g 
for 3 min. The collected solution containing the antibody dissociated from the Aß 
peptide was neutralized to pH 7.0 with 1 M Tris buffer, pH 9.5. The dissociated 
sera were assayed by ELISA for antibody titer. Aß1–40 (Global Peptide)-coated 
96-well microtiter plates (MaxiSorp; Nunc) were incubated with dissociated 
serum samples. A biotinylated goat-anti mouse IgG (heavy and light chain; 
Vector Laboratories,Burlingame, CA) at a 1:5000 dilution followed by peroxidase-
conjugated streptavidin (Amersham Biosciences) was used to detect serum anti-
Aß binding activity. 
 
Tissue Preparation. On the day of sacrifice the mice were overdosed with 100 
mg/kg of Nembutal sodium solution (Abbott laboratories, North Chicago IL). The 
mice were perfused intracardially with 25ml 0.9% saline. The right brain 
hemisphere was dissected and stored for later analysis. These dissections were 
rapidly frozen in dry ice and stored at -80oC.  The left hemisphere was removed 
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and immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours, then 
passed through 10, 20 and 30% sucrose solutions for 24 hours each.  
 
Histology. Horizontal sections of 25μm thickness were collected using a sliding 
microtome and stored in DPBS + azide. A series of 8 sections spaced 
approximately 600μm apart were stained immunohistochemically for Aß (6E10 
mouse monoclonal anti-Aß, Biosource, Camarillo, CA, 1:30,000) to determine the 
degree of Aß removal and for CD45 (rat monoclonal anti-CD45, Serotec, 
Raleigh, NC 1:5000) to determine the extent of microglial activation. A series of 
tissue sections 600µm apart were stained using 0.2% Congo red solution in NaCl 
saturated 80% ethanol. Another set of sections were stained for hemosiderin 
using 2% potassium ferrocyanide in 2% hydrochloric acid (Prussian Blue) for 15 
minutes followed by a counterstain in a 1% neutral red solution for 10 minutes.  
Quantification of Congo red staining, CD45 and Aß immunohistochemistry 
was performed using the Image-Pro Plus (Media Cybernetics, Silver Spring, MD) 
software to analyze the percent area occupied by positive stain. One region of 
the frontal cortex and three regions of the hippocampus were analyzed (to 
ensure that there was no regional bias in the hippocampal values). The initial 
analysis of all Congo red profiles provided a total Congo red value. A second 
analysis was performed after manually editing out the parenchymal amyloid 
deposits to yield a percent area restricted to vascular Congo red staining 
(Wilcock et al., 2006). To estimate the parenchymal area of Congo red, we 
subtracted the vascular Congo red values from the total Congo red values. For 
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the hemosiderin staining, the numbers of Prussian blue positive deposits were 
counted over the entire cortex and hippocampus on all sections and the average 
number of hemosiderin deposits per section was calculated. To assess possible 
treatment-related differences in pathology, the histochemical values for each 
treatment group were analyzed by one-way ANOVA followed by Fischer’s LSD 
means comparisons using StatView (SAS Institute Inc, NC). 
 
RESULTS 
To study the dose response of deglycosylated antibodies on fibrillar and 
diffuse Aß removal, cerebral amyloid angiopathy (CAA), microhemorrhage, and 
cognition, we used transgenic mice containing a double mutation, K670N and 
M671L, in the human APP gene under the control of a hamster prion promoter 
(Hsiao et al., 1996). We passively immunized 19 month old APP mice with 
deglycosylated C-terminal (aa35-40) anti-Aß antibodies (D-2H6) for 12 weeks 
with one of the following doses; 3mg/kg, 10mg/kg, or 30mg/kg.  
 
Dose-dependent increases in serum Aß and circulating anti-Aβ antibody 
titer: Antibody titer in the final serum bleeds displayed a dose-dependent 
response where the highest dose of deglycosylated antibody, 30mg/kg, showed 
the greatest anti-Aß IgG titer at approximately 2500nM, while the 10mg/kg dose 
was intermediate at 1500nM, and the 3mg/kg dose had the lowest titer at 250nM 
(Fig. 1B). Anti-Aß antibodies were not detected in the APP transgenic mice 
treated with the control antibody or in the nontransgenic mice.  Similar to 
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antibody titer, serum levels of circulating total Aß displayed a dose-dependent 
response, with total serum Aß increasing in parallel with increasing doses of 
deglycosylated antibody (Fig. 1A).    
 
Reversal of cognitive deficits with low doses of deglycosylated anti-Aß 
antibodies: After 12 weeks of antibody treatment, behavioral analysis using the 
radial-arm water maze (RAWM) showed spatial reference memory deficits in the 
control APP transgenic group treated with the anti-drosophila amnesiac antibody 
when compared to the nontransgenic mice (Fig. 1). The control APP transgenic 
group performed the maze with the greatest number of errors and the non-
transgenic mice performed with the least errors.  On the second day of testing 
the mice treated with 3mg/kg of D-2H6 performed equivalently to the 
nontransgenic mice with performance errors near 0.5 per trial (Fig. 1).  The APP 
transgenic mice treated with 10mg/kg or 30mg/kg doses of de2H6 performed at 
an intermediate level between the nontransgenic mice and APP transgenic mice 
treated with control antibody and were not significantly different from either 
group.  
 
Total Aß immunohistochemistry is reduced following treatment with 
deglycosylated antibodies: 
 Total Aß consists of both compact and diffuse amyloid deposits, and can 
be detected using immunohistochemical methods.  In old APP transgenic mice 
the pattern of total Aß immunohistochemistry resembles that of human AD 
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pathology. In the frontal cortex we observe a typical pattern of diffuse Aß staining 
as well as, compact, intensely-stained deposits that are positive for amyloid when 
stained with Congo red or thioflavine-S (Fig. 3A). In the hippocampus, Aß 
deposits are concentrated around the hippocampal fissure and the CA1 region 
(Fig. 3B) with fewer deposits throughout the dentate gyrus and remainder of 
hippocampal tissue. The appearance of Aβ immunostaining after administration 
of different doses of D2H6 is presented in the frontal cortex (Fig. 3C, E, G) and 
hippocampus (Fig. 3D, F, H). Quantification of the percent area occupied by 
positive staining showed a reverse dose response trend where the lowest dose 
significantly reduced total Aß in the frontal cortex by 48% while the intermediate 
dose and high doses were less effective at reducing Aß (Fig. 4).  A similar trend 
was observed in the hippocampus, although the reductions caused by the lowest 
dose were not significant (Fig. 4). 
 
Deglycosylated anti-Aß immunization reduces fibrillar Aß: 
Congo red binds preferentially to the beta-pleated sheet conformation of 
fibrillar Aß and is the standard protocol for detecting compact amyloid plaques. 
Congo red histology in the frontal cortex of mice treated with deglycosylated 
antibody is presented in Fig 5.  Both the quantity and size of fibrillar, compact 
plaques in the parenchyma can be appreciated. In many fields an apparent 
increase in vascular deposits could also be observed and are indicated with 
arrows in Fig 5. Quantification of the total area occupied by Congo red stain 
revealed significant reductions with both the 3mg/kg and 10mg/kg doses in the 
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frontal cortex (Fig 6A).  Quantification of the parenchymal amyloid deposits 
showed that the 3 mg/kg dose resulted in the greatest reduction of compact 
plaque by approximately 70%, followed by the intermediate and highest doses of 
10 and 30 mg/kg with a 40% reduction (Fig. 6B).  There was an increase in 
vascular amyloid in both regions (Fig. 6C). Compared to the control group, all 3 
doses of deglycosylated antibody resulted in a significant elevation of vascular 
Congo red, albeit the vascular deposits were still considerably fewer than the 
parenchymal amyloid deposits. It is important to recognize that variability is high 
when the fractional stained areas are as low as found for vascular deposits in this 
experiment (less than 0.25% of area). The 30 mg/kg dose increased CAA to the 
same extent as the 3 mg/kg dose without producing a comparable reduction in 
compact amyloid.  
 
Deglycosylated antibody administration does not cause an increase in 
microhemorrhage: Prussian blue histochemistry is the classic method for 
demonstrating iron in tissues.  Hemosiderin (iron storage granules) may be 
present in areas of hemorrhage or may be deposited in tissues with iron 
overload. After 3 months of passive immunization with a deglycosylated C-
terminal antibody the average number of positive Prussian blue profiles per 
section was less than 1 for all antibody doses, despite the increase in vascular 
amyloid (Fig. 7).  For comparison purposes, we have included in Fig 7 our prior 
data obtained with the native antibody (2H6) at 10 mg/kg, which resulted in 
greater than 3 positive profiles per section (Wilcock et al., 2006).  
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Microglial activation was measured with CD45 immunohistochemistry.  
CD45 is a protein tyrosine phosphatase that is expressed when microglia are 
activated.  CD45 positive microglia are observed surrounding compact, Congo 
red positive amyloid plaques. One method of microglial activation is through the 
Fcγ receptor, a method that is greatly diminished with the deglycosylated 
antibody. In a time study conducted by Wilcock et al., CD45 expression after 
passive administration of intact C-terminal anti-Aß antibodies showed that CD45 
expression is significantly up-regulated at the 1 and 2 month time point and 
returns to baseline at the 3 month time point (Wilcock et al., 2004b).  In this 
study, CD45 immunohistochemistry showed no differences between the 3 doses 
of deglycosylated antibody and the control group, which confirms that the 
deglycosylated antibody is not activating microglia at the 3 month time point 
(Table 1). 
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DISCUSSION  
 We have previously shown that deglycosylation of an anti-Aß antibody 
retains the antibody’s ability to reduce parenchymal amyloid deposits, to reverse 
cognitive deficits, and to reduce the potentially adverse changes such as 
microglial activation, CAA and microhemorrhage (Wilcock et al., 2006) (Carty et 
al., 2006). The data presented in the current experiment suggest that peripheral 
administration of high doses (>10 mg/kg) of deglycosylated anti-Aß antibodies in 
old APP transgenic mice are not as effective at reducing Aß or reversing 
cognitive deficits as lower doses.                                
In the present study, the lowest dose (3 mg/kg) of D-2H6 reduced diffuse 
Aß, fibrillar Aß, and reversed cognitive deficits to the greatest extent compared to 
higher doses of D-2H6 or control IgG.  Similar results were presented by Gitter 
and colleagues at a scientific meeting (Gitter et al.,2002).  In their work, a dose 
response study using an intact mid-domain antibody administered for 5 months 
to PDAPP mice showed that the highest dose failed to reduce Aß plaque burden 
and at the same time sequestered the most peripheral Aß in the plasma, while 
the lower doses sequestered less Aß in the serum and reduced total plaque 
burden to a greater extent.  Similar to our study, plasma Aß and IgG levels 
showed a dose response relationship where the highest dose of antibody 
sequestered the highest levels of plasma Aß. However, in this study as well as in 
Gitter’s study, peripheral Aß sequestration did not correlate to reductions in brain 
Aß levels. One possible explanation for this discordance is that much of the 
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increase in plasma Aß results from retarded Aß degradation due to antibody 
sequestration rather than simply increased clearance from the brain.     
 Deglycosylation of anti-Aß antibodies significantly reduces the affinity of 
the antibody for Fcγ receptors I, II, III located on effector cells, and the 
complement cascade initiator, C1q (Carty et al., 2006). Immunohistochemical 
analyses of APP brain sections after intracranial injections of intact or 
deglycosylated antibody confirmed that deglycosylation does not activate 
microglia as measured with antibodies against FcγRII/III and CD45 when 
compared to mice treated with control or native intact anti-Aß IgG (Carty et al., 
2006).  In addition to intracranial studies, our lab performed a direct comparison 
of native and deglycosylated anti-Aß antibodies in a long-term systemic study.  
After 4 months of treatment, reversal of cognitive deficits and reductions in 
fibrillar and diffuse Aß were found with both the deglycosylated and intact 
antibody, although the deglycosylated antibody appeared slightly less active. 
However, the incidence of CAA and microhemorrhage were significantly reduced 
with the deglycosylated antibody compared to its native counterpart (Wilcock et 
al., 2006).  
Although deglycosylation reduces the affinity of IgG for Fcγ receptors, the 
interaction of immunoglobin with neonatal Fc receptor (FcRn), also known as the 
Fc transport receptor (FcTR), is not affected by the removal of carbohydrate side 
chains (Hobbs et al., 1992). The FcRn is structurally and functionally distinct from 
the Fcγ receptors (Ravetch et al., 2001) (Brambell et al., 1964).   The functional 
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roles of the FcRn are to recycle IgG and transport IgG bidirectionally across 
epithelial barriers (Lencer et al., 2005).  
FcRn expression is found at the brain microvasculature and choroid 
plexus epithelium on the blood brain barrier (BBB) (Schlachetzki et al., 2002).   
The expression of the FcRn in the blood brain barrier may mediate the 'reverse 
transcytosis' of IgG and immune complexes (ICs) in the brain to blood direction 
(Schlachetzki et al., 2002). In a study by Banks et al., (Banks et al., 2002), brain 
uptake of anti-Aß antibodies and albumin enter the brain at similar rates for the 
first hour after i.v. injection. However in later time points, the influx rate of anti-Aß 
antibody was significantly reduced to less than 1%. The reduction in influx rate 
was caused by antibody efflux mechanisms.  In order for new antibody to enter 
the brain, antibody in the brain must depart. Zhang and Pardridge (Zhang et al., 
2001) tested brain efflux mechanisms of IgG with intracranial injections of 
radiolabeled IgG2a and found that efflux mechanisms were saturated with the 
addition of excess Fc fragments or intact IgG molecules, resulting in complete 
suppression of efflux mechanisms.  However, efflux mechanisms were not 
inhibited by high concentrations of F(ab)2 fragments or albumin (Zhang et al., 
2001).  These findings support the fact that the receptors necessary for IgG 
transport require the Fc portion on IgG to be active. Furthermore, Deane and 
colleagues  (Deane et al., 2005) found that the FcRn transport system is the 
main mechanism mediating the transcytosis of Aß-anti-Aß immune complexes 
(ICs) from the brain to blood in old Tg2576 mice. This group also found that 
antibody mediated Aß clearance from the brain is abolished in old FcRn -/- mice.  
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Similar to Zhang and Pardridge, Deane and colleagues demonstrated that the 
addition of excess IgG inhibited the clearance of immune complexes from the 
brain. Therefore, high concentrations of immunoglobin will saturate the FcRn 
receptors with antibody not bound to antigen, hinder the FcRn binding of Aß-anti-
Aß immune complexes, and ultimately result in the inhibition of Aß clearance 
from the brain.  The saturation of FcRn may explain why high doses of 
deglycosylated antibody are not as effective at reducing diffuse and fibrillar Aß 
compared to antibodies administered at lower doses.  The saturation of this efflux 
system may also result in Aß building up along the brain microvasculature and 
lead to the formation of CAA. Ironically, our original purpose for conducting this 
study, (to contrast qualitative versus quantitative explanations for the benefits of 
deglycosylation) could not be addressed, as the high doses of antibody failed to 
clear more amyloid.  
 In summary, we have shown that the efficacy of passively administered 
deglycosylated antibodies depend upon drug dose.  Our study demonstrated that 
the lowest dose of deglycosylated anti-Aß antibody was the most efficacious at 
reducing total Aß, fibrillar Aß, and reversing cognitive deficits when tested in old 
APP transgenic mice.  Antibody influx and efflux mechanisms may play a major 
role in Aß clearance and in the efficacy of an antibody.  Saturation of these 
mechanisms with uncomplexed antibody may greatly reduce antibody efficacy, 
emphasizing the requirement for precise titration of dose-response 
characteristics in human trials of anti Aß immunotherapy.  
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Figure 1: DOSE RELATED INCREASES IN SERUM LEVELS OF Aß AND 
ANTI-Aß ANTIBODY AFTER DEGLYCOSYLATED ANTI-Aß ANTIBODY 
ADMINISTRATION.  Panel A shows the average amounts of circulating Aß in 
sera and Panel B shows average amounts of circulating anti-Aß antibodies 24 
hours following the final antibody injection in APP transgenic mice receiving 
either control antibody (Cont) or anti-Aß antibody at doses of 3, 10, or 30 mg/kg, 
nontransgenic (NTg) mice received no treatment. ** indicates P<0.001 compared 
to APP mice given control antibody injections.  
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Figure 2: LOW DOSES OF DEGLYCOSYLATED ANTIBODY IMPROVE 
COGNITION AFTER 12 WEEKS OF TREATMENT. Radial Arm Water Maze 
performance is plotted as the mean number of errors per block of 3 trials over a 
two day trial period following three months of immunization with deglycosylated 
anti-Aß. The graph shows the average number of errors for APP transgenic mice 
treated with either 3 mg/kg deglycosylated anti-Aß antibody (c, dashed line), 10 
mg/kg deglycosylated 2H6 anti-Aß antibody (□, dashed line), 30 mg/kg 
deglycosylated anti-Aß antibody (U, dashed line), control anti-AMN antibody (■, 
solid line) and nontransgenic mice (●, solid line). * indicates P<0.05 between the 
3mg/kg treated group and the control IgG treated group. 
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Figure 3: TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED AFTER 
SYSTEMIC ADMINISTRATION OF ANTI-Aß ANTIBODIES. Panels A-H show 
Aß immunohistochemistry from APP transgenic mice in the frontal cortex (Panels 
A, C, E, and G) and CA1 region of the hippocampus (Panels B, D, F, H). Mice 
were treated with control antibody (anti-AMN 2908; Panels A and B), 3 mg/kg 
deglycosylated anti-Aß antibody (Panel C and D), 10 mg/kg deglycosylated 2H6 
anti-Aß antibody (Panel E and F), or 30 mg/kg deglycosylated anti-Aß antibody 
(Panels G and H). Both the number of parenchymal deposits and their intensity 
appear less after immunotherapy.  Scale bar in panel A = 25µm for all panels. 
Abbreviations:  CA1:  CA1 pyramidal cell layer; F:  fissure 
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Figure 4: TOTAL Aß IMMUNOHISTOCHEMISTRY IS SIGNIFICANTLY 
REDUCED IN THE FRONTAL CORTEX AFTER SYSTEMIC TREATMENT 
WITH THE 3 MG/KG DOSE OF DEGLYCOSYLATED ANTIBODY. The graph 
shows the quantification of percent area of total Aß staining in the frontal cortex 
(A) and hippocampus (B) after 12 weeks of treatment with control IgG (CTRL), 
3mg/kg, 10 mg/kg, and 30 mg/kg doses of deglycosylated anti-Aβ antibody.         
* indicates P<0.05 when compared to mice treated with control antibody. 
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Figure 5: CONGO RED STAINING IN THE FRONTAL CORTEX AFTER AFTER 
IMMUNOTHERAPY.  (A) anti-AMN control antibody; (B) 30 mg/kg dose D-2H6 
anti-Aß antibody; (C) 10 mg/kg ; (D) 3 mg/kg dose. Scale bar in panel A = 50μm.  
Arrows shown in panels B, C, and D indicate vessels that are positively stained 
for CAA. 
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Figure 6: LOWER DOSES OF DEGLYCOSYLATED ANTIBODY CAUSE 
GREATER DECREASES IN FIBRILLAR Aβ.  Panel A shows the quantification 
of percent area of total Congo red staining in the frontal cortex and hippocampus 
after 12 weeks of anti-Aß antibody passive immunization in frontal cortex (solid 
bars) and hippocampus (open bars). Panel B shows quantification of 
parenchymal Congo red in the frontal cortex (solid bars) and hippocampus (open 
bars). Panel C shows quantification of vascular Congo red in the frontal cortex 
(solid bars) and hippocampus (open bars).  * indicates p<0.05, ** indicates 
p<.001 compared with control antibody. 
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Figure 7: INCIDENCE OF MICROHEMORRHAGE IS NOT CHANGED WITH 
ANY DOSE OF DEGLYCOSYLATED ANTIBODY. The graph shows 
quantification of positive Prussian blue profiles per section in APP transgenic 
mice treated with control anti-AMN IgG, 3mg/kg, 10 mg/kg, or 30 mg/kg doses of 
deglycosylated antibody for 3 months (Mean +/- SEM).  Incidence of 
microhemorrhage after intact 2H6 antibody at 10 mg/kg observed by Wilcock et 
al (2006) was much higher. 
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Table 1.  CD45 expression determined by immunohistochemistry in APP 
transgenic mice following 3 months of passive immunization. 
 
Treatment Anterior Cortex Hippocampus 
Control anti-AMN 
antibody 
2.912 ± 19% 2.693 ± 59% 
3 mg/kg of D-2H6 2.491 ± 42% 2.898 ± 26% 
10 mg/kg of D-2H6 2.736 ± 43% 2.517 ± 23% 
30 mg/kg of D-2H6 2.331 ± 32% 2.310 ± 15% 
Values are mean ± SEM  
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ABSTRACT 
 
Passive immunization in transgenic mouse models of Aß amyloidogenesis 
has shown that anti-Aß antibodies have the ability to prevent and reduce neuritic 
plaques, to reverse cognitive decline, and have the tendency to increase the 
occurrence and severity of CAA and microhemorrhage.  
In the current study we compare antibodies directed against different 
epitopes of the Aß peptide for their ability to clear abeta deposits, mitigate or 
exacerbate CAA and microhemorrhages, as well as their effects on behavior. 
Tg2576 mice, 21-22 months of age, were treated with one of the following anti-
Aß antibodies; N-terminal antibody (Aß1-5  IgG2b), mid domain antibody (Aß16-28  
IgG2b), or C-terminal antibody (Aß33-40  IgG2b). The fourth group received a 
control IgG antibody against drosophila amnesiac protein (mouse monoclonal 
anti-drosophila amnesiac protein IgG2b).  All mice were given weekly 
intraperitoneal injections of the appropriate antibody at a concentration of 
10mg/kg for 12 weeks.   
The N- and C-terminal anti-Aß antibodies reversed cognitive deficits and 
significantly reduced diffuse and compact plaque loads, but at the same time 
increased CAA and microhemorrhage compared to mice that received control 
IgG.  In contrast, the mid domain antibody significantly reduced diffuse Aß and 
showed no exacerbation of CAA or microhemorrhage but also failed to improve 
memory.  These data suggest that the exacerbation of CAA and incidence of 
hemorrhage are a result of compact amyloid clearance.  Furthermore,  a 
component of compact plaques appears responsible for memory loss. 
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INTRODUCTION 
The amyloid ß-protein (Aß) is derived from the ß-amyloid precursor protein 
(APP) by the cleavages of ß- and γ-secretase (Seubert et al., 1993). Depending 
on the exact point of cleavage, three principal forms of Aß, comprising 38, 40, or 
42 amino acids residues are produced. The overproduction and accumulation of 
Aß is the precipitating event that cascades to the development of Alzheimer’s 
disease (AD) (Hardy and Selkoe, 2002). Thus, based upon this concept of 
amyloid accumulation, one major target of therapeutic intervention in AD has 
been to actively clear Aß from the brain with immunotherapy. 
Both active and passive immunotherapies against Aß have shown 
promising results in humans and in transgenic mice. Work in mouse models 
show remarkable efficacy in reducing amyloid loads and restoring cognitive 
function.  Passive immunization, however, permits careful titration of antibody 
dosage, allows for reversibility, and enables scientists to modify and target 
specific epitopes of a protein.  
Most antibodies developed with active immunization are directed against 
the N-terminal amino acids of the Aß peptide (Dickey et al., 2001) (Schenk et al., 
1999) (Hock et al., 2002) (Lee et al., 2005). Solomon and colleagues reported 
that amino acid residues 3-6 were the minimal effective epitope in raising 
antibodies against Aß because these N-terminal residues were responsible for 
the aggregation of Aß (Solomon et al., 1996). Initial studies showed that 
antibodies specific for the N-terminal region of Aß could prevent the formation of 
 53
fibrillar amyloid in vitro (Solomon et al., 1996) (Solomon et al., 1997).  Peptides 
with this epitope specificity have been found effective at reducing amyloid and 
reversing cognitive deficits in mouse models (Bard et al., 2000) (Kotilinek et al., 
2002). However, antibodies directed against the mid domain and C-terminal of 
the Aß peptide have also been effective at reducing Aß load (DeMattos et al., 
2001) and reversing cognitive deficits (Wilcock et al., 2004b).  
More recently, immunization against Aß has revealed adverse effects.  
Despite significant reductions in amyloid load and improvements in cognition, the 
exacerbation of cerebral amyloid angiopathy (CAA) and microhemorrhage after 
chronic administration of monoclonal antibodies are two unwarranted effects. 
Pfeifer and colleagues passively immunized 21-month-old APP23 mice for 6 
weeks with an N-terminal antibody and found a significant reduction in diffuse 
Aß42 but not Aß40, as well as a two fold increase in CAA-associated 
microhemorrhages (Pfeifer et al., 2002). Racke and colleagues found that N-
terminal antibodies bound to CAA associated microvessels significantly better 
than mid-domain antibodies (Racke et al., 2005).   DeMattos and colleagues 
used a mid domain antibody and found that although they could not detect the 
antibody in the brain, it was able to reduce diffuse plaque in the brain by rapidly 
sequestering plasma Aß (DeMattos et al., 2001). Our lab passively immunized 
Tg2576 mice with a C-terminal antibody and found a significant reduction in both 
diffuse and fibrillar parenchymal Aß as well as improvements in cognition, 
despite increased CAA and microhemorrhages (Wilcock et al., 2004b).   
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The purpose of this experiment is to compare  antibodies directed against 
different epitopes of the Aß protein to determine whether they are equally 
effective in modulating amyloid and cognition. Furthermore, comparison of 
antibodies with different epitopes will identify if the increased vascular amyloid 
and hemorrhage are a general property of antibody-associated Aß clearance, or 
if antibodies with different epitope specificities could avoid these potentially 
adverse consequences.   
 
MATERIALS AND METHODS 
 
Experimental Design. All APP Tg2576-derived mice were bred in our facility at 
the University of South Florida and genotyped using previously described 
methods (Holcomb et al., 1998) (Gordon et al., 2002).  Importantly, we have 
intentionally bred out the retinal degeneration 1 mutation from this colony to 
avoid the inclusion of occasional mice that are blind due to homozygous 
inheritance of this mutation contributed by the SJL/J background (Alamed et al., 
2006). Twenty-four Tg2576 mice (21-22 months of age) were assigned to one of 
4 groups. The first group received the N-terminal antibody anti-Aß1-5  IgG2b 
(2324, Rinat Neurosciences, Palo Alto, CA). The second group received the mid 
domain antibody anti-Aß16-28  IgG2b (2289,  Rinat Neurosciences, Palo Alto, CA). 
The third group received the C-terminal antibody anti-Aß33-40  IgG2b (2H6, Rinat 
Neurosciences, Palo Alto, CA).  The fourth group received the control IgG 
antibody against drosophila amnesiac protein (mouse monoclonal anti-drosophila 
amnesiac protein IgG2b; Rinat Neurosciences, Palo Alto, CA).  All mice were 
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given weekly intraperitoneal injections of the appropriate antibody at a 
concentration of 10mg/kg for 12 weeks.  A fifth group of age matched, 
nontransgenic mice was used as a control in the behavioral sector of the 
experiment.  
 
Behavioral Paradigm. Following 3 months of treatment, the mice were subjected 
to a two day behavioral paradigm consisting of the radial-arm water maze 
(RAWM), followed by an open pool visible platform task. The radial arm water 
maze task was run as previously described (Wilcock et al., 2004b). Briefly, the 
RAWM contained 6 arms radiating out of an open central area, with a hidden 
escape platform located at the end of one of the arms (Alamed et al., 2006). On 
day 1, 15 trials were run in 3 blocks. The start arm was varied for each trial, with 
the goal arm remaining constant for both days. For the first 11 trials, the platform 
was alternately visible then hidden (hidden for the last 4 trials). On day two, the 
mice were run in exactly the same manner as day 1 except that the platform was 
hidden for all trials. The number of errors (incorrect arm entries) were measured 
in a one minute time frame. Mice failing to make an arm choice in 15 seconds 
were assigned 1 error. In order to minimize the influence of individual trial 
variability, each mouse's errors for three consecutive trials were averaged 
producing 5 data points for each day which were analyzed statistically by ANOVA 
using StatView (SAS Institute Inc., NC). Next, the mice were run in a one day 
open pool task with a visible platform to verify swimming ability and eyesight. No 
mice demonstrated impaired ability to swim or to see.  
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Tissue Preparation. On the day of sacrifice the mice were overdosed with 100 
mg/kg Nembutal sodium solution (Abbott laboratories, North Chicago IL). The 
mice were perfused intracardially with 25 ml of 0.9% saline. The right brain 
hemisphere was dissected, rapidly frozen on dry ice and stored at -80oC.  The 
left hemisphere was removed and immersion fixed in freshly prepared 4% 
paraformaldehyde for 24 hours, then passed through 10, 20 and 30% sucrose 
solutions for 24 hours each.  
 
Histology. Horizontal sections of 25μm thickness were collected using a sliding 
microtome and stored in DPBS + azide. A series of 8 sections spaced 
approximately 600μm apart were stained via free-floating immunohistochemically 
for total Aß (rabbit polyclonal anti-Aß, gift from Dr. Gottschall USF, 1:10,000) to 
determine the degree of Aß removal and for CD45 (rat monoclonal anti-CD45, 
Serotec, Raleigh, NC 1:5000) to determine the extent of microglial activation. The 
free-floating immunohistochemistry protocol was previously described by Gordon 
et. al., (Gordon et al., 2002).  A series of tissue sections 600µm apart were 
stained using 0.2% Congo red solution in NaCl saturated 80% ethanol. Another 
set of sections were stained for hemosiderin using 2% potassium ferrocyanide in 
2% hydrochloric acid (Prussian Blue) for 15 minutes followed by a counterstain in 
a 1% neutral red solution for 10 minutes.  
Quantification of Congo red staining, CD45 and Aß immunohistochemistry 
was performed using the Image-Pro Plus (Media Cybernetics, Silver Spring, MD) 
software to analyze the percent area occupied by positive stain. One region of 
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the frontal cortex and three regions of the hippocampus were analyzed (to 
ensure that there was no regional bias in the hippocampal values). The initial 
analysis of all Congo red profiles provided a total Congo red value. A second 
analysis was performed after manually editing out the parenchymal amyloid 
deposits to yield a percent area restricted to vascular Congo red staining 
(Wilcock et al., 2006). To estimate the parenchymal area of Congo red, we 
subtracted the vascular Congo red values from the total Congo red values. For 
the hemosiderin staining, the numbers of Prussian blue positive deposits were 
counted over the entire cortex and hippocampus on all sections and the average 
number of hemosiderin deposits per section calculated. To assess possible 
treatment-related differences in pathology, the histochemical values for each 
treatment group were analyzed by one-way ANOVA followed by Fischer’s LSD 
means comparisons using StatView (SAS Institute Inc, NC). The histological data 
presented in the manuscript are all normalized to the control group.   
 
RESULTS 
Reversal of cognitive deficits with N- and C-terminal anti-Aß antibodies: 
After 12 weeks of antibody treatment, behavioral analysis using the radial-
arm water maze (RAWM) showed spatial reference memory deficits in the control 
APP transgenic group treated with the anti-drosophila amnesiac antibody when 
compared to the nontransgenic mice (Fig. 1). The control APP transgenic group 
performed the maze with the greatest number of errors and the non-transgenic 
mice performed with the fewest errors.  On the second day of testing the mice 
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treated with the N- and C-terminal antibodies performed significantly better than 
the APP mice treated with control IgG with performance errors near 1 per trial 
(Fig. 1).  The APP transgenic mice treated with the mid domain antibody did not 
improve in the behavioral paradigm.  The average number of errors for the 
groups treated with the mid domain antibody and control IgG were around 3 per 
trial at the end of the second day (Fig. 1). The one day open pool task 
determined that all mice had the ability to swim and see a visible platform (data 
not shown). 
Total Aß is reduced following treatment with all 3 antibodies: 
 Total Aß consists of both compact and diffuse amyloid deposits that can 
be detected using immunohistochemical methods.  In old APP transgenic mice 
the pattern of total Aß immunohistochemistry resembles that of human AD 
pathology. In the frontal cortex we observe a typical pattern of diffuse Aß staining 
as well as, compact, intensely-stained deposits that are positive for Aß (Fig. 2A). 
In the hippocampus, Aß deposits are concentrated around the hippocampal 
fissure and the CA1 region with fewer deposits throughout the dentate gyrus and 
remainder of hippocampal tissue (Fig. 2B). The appearance of Aß 
immunostaining in the frontal cortex and hippocampal regions are shown in 
Figure 2. A qualitative reduction in diffuse Aß with remaining compact deposits 
can be seen in both the cortex and hippocampus after administration of all 3 
antibodies compared to the control IgG (Figure 2). Quantification of the percent 
area occupied by positive staining showed significant reductions in total Aß by all 
3 antibodies in both the cortex and hippocampus (Fig. 3).   The values shown are 
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the percent area of Aß normalized to the control group.   
 
N- and C-terminal, but not mid domain anti-Aß antibodies cause reductions 
in fibrillar Aß:  
Congo red  binds preferentially to the beta-pleated sheet conformation of 
fibrillar Aß and detects compact amyloid plaques. Congo red histology in the 
frontal cortex and hippocampal fissure of mice treated with control IgG, N-
terminal, mid domain, and C-terminal antibody are presented in figure 4.  Many 
congophilic plaques can be detected in control IgG and mid domain antibody 
treated APP mice.  Following anti-Aß treatment, an apparent increase in vascular 
deposits could also be observed and are indicated with arrows (Fig 4). These 
vascular deposits were only apparent in areas devoid of parenchymal amyloid. 
Quantification of the total area occupied by Congo red stain revealed significant 
reductions with both the N-terminal and C-terminal anti-Aß antibodies in the 
frontal cortex and hippocampus (Fig 5A).  The percent area positive for Congo 
red was normalized to the control values; this gave the control groups a value of 
one for all measures.  
Quantification of the parenchymal amyloid deposits showed that the C-
terminal antibody resulted in the greatest reduction of compact plaque by 
approximately 95%, followed by the N-terminal antibody with a 60% reduction in 
the frontal cortex and hippocampus (Fig. 5B).  The mid domain antibody failed to 
reduce compact deposits. The C-terminal antibody caused an almost complete 
clearance of parenchymal deposits in both the hippocampus and cortex however; 
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there was a two-fold increase in vascular amyloid compared to mice that 
received control IgG (Fig. 5C).   
 
C-terminal anti-Aß antibodies cause significant increases in activated 
microglia surrounding amyloid deposits: 
Microglial were visualized with CD45 immunohistochemistry.  CD45 is a 
protein tyrosine phosphatase that is expressed when microglia are activated.  
The fibrillar Aß plaques formed by APP transgenic mice are accompanied by 
local activation of microglia and are decorated with CD45 positively stained 
microglia (Gordon et al., 2002).  CD45 stain in the group treated with the C-
terminal antibody revealed intensely stained microglia surrounding the remaining 
parenchymal, compact amyloid deposits while the pattern and intensity of 
microglial expression from the mid domain and N-terminal antibodies showed no 
differences compared to controls.  However, quantification of the percent area of 
CD45 immunohistochemistry showed no differences between the 3 antibodies 
tested in either the frontal cortex or hippocampus (Fig. 6A & 6B).  Since the 
majority of activated microglia are associated with compact deposits, these 
measurements reflect the amount of microglial activation per deposit.  
Quantification of Congo red histochemistry revealed significant reductions in 
compact plaque with antibody treatment; therefore we calculated the ratio of 
CD45 immunohistochemistry to total Congo red percent area to estimate the 
microglial activation per amyloid deposit.  Calculating this ratio demonstrated 
increased microglial expression of CD45 associated with the remaining amyloid 
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deposits in both the frontal cortex (Fig. 6C) and hippocampus (Fig. 6D) only after 
treatment with the c-terminal antibody. No change in the ratio was found 
following treatment with the N-terminal or mid domain anti-Aß antibodies in either 
the frontal cortex (Fig.6C) or hippocampus (Fig. 6D).  
Both N- and C-terminal anti-Aß antibodies cause an increase in 
microhemorrhage:  
Prussian blue histochemistry is the classic method for demonstrating iron 
in tissues.  Hemosiderin (iron storage granules) may be present in areas of 
hemorrhage or may be deposited in tissues with iron overload. After 3 months of 
passive immunization with N-terminal, mid domain, or C-terminal anti-Aß 
antibodies, we find significant increases in the number of positive Prussian blue 
profiles per section with the N-terminal and C-terminal antibodies (Fig. 7).  We 
found an average of 2 positive Prussian blue profiles per section with the N-
terminal antibody and an average of 3 positive profiles per section with the C-
terminal antibody.   
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DISCUSSION 
In the present study, we demonstrated that antibodies with different 
epitope specificities have distinct effects on different Aß pools and, ultimately, 
different behavioral outcomes. In addition, we investigated the extent of vascular 
Aß accumulation and microhemorrhage after systemic treatment with antibodies 
directed against different epitopes of Aß.  We found that increases in vascular 
amyloid correlate with the degree of compact, parenchymal Aß clearance and 
epitope specificity is not a critical factor in directing the vascular accumulation. 
After 3 months of weekly intraperitoneal injections, cognitive 
improvements were seen in the mice treated with the N-terminal and C-terminal 
anti-Aß antibodies, while the mid domain antibody failed to show behavioral 
improvements.  Despite the differences found with the behavioral data, all three 
antibodies resulted in similar reductions in total Aß immunostaining. Meanwhile, 
only the N- and C-terminal antibodies were able to significantly reduce fibrillar Aß 
as measured with Congo red histochemistry. Interestingly, of the 3 antibodies 
tested, the C-terminal antibody caused the greatest reductions in Aß with more 
than 90% of the parenchymal deposits removed. Although these reductions were 
associated with a two-fold increase in vascular Aß, the remaining vascular loads 
were still much less than the total brain amyloid loads, suggesting both a 
redistribution of parenchymal amyloid into the vasculature and a dramatic 
clearance of Aß from the brain.  
It has been previously hypothesized that microglial activation via anti-Aß 
antibodies is required for the removal of fibrillar deposits (Wilcock et al., 2001) 
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(Schenk et al., 1999) (Wilcock et al., 2004) (Bard et al., 2000). Here we 
demonstrate that the C-terminal antibody causes the greatest reduction in 
compact amyloid plaques and the remaining amyloid plaques have the greatest 
number of associated microglia.  
Our results support previous findings that an N-terminally directed and C-
terminally directed antibody could exacerbate CAA and result in increased 
microhemorrhage (Racke et al., 2005) (Pfeifer et al., 2002) (Carty et al., 2006).  
Interestingly, the N-terminal antibody was not as effective at reducing Aß loads 
and did not significantly increase CAA as compared to the C-terminal antibody. 
Despite the lack of CAA, the N-terminal antibody increased microhemorrhage 
more than 2-fold compared to mice treated with control IgG. It has been 
previously noted that N-terminal antibodies bound to deposited Aß in tissue 
sections and to CAA-bearing vessels (Racke et al., 2005) (Bard et al., 2003). A 
single application of N-terminally directed antibodies under a cranial window 
showed modest clearance of CAA while chronic topical infusion resulted in robust 
clearance of CAA; determined with quantitative in vivo image analysis (Prada et 
al., 2007).  Vascular and parenchymal deposits can be removed with N-terminally 
directed antibodies.  However, the removal of vascular amyloid may further 
disrupt the integrity of the vessel or cause localized vascular inflammation and 
exacerbate microhemorrhage. 
The mid domain antibody did not lead to increased vascular Aß or 
incidence of microhemorrhage. Binding characterizations of a different mid 
domain antibody, 266, demonstrated binding only to soluble Aß but not to 
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deposited Aß in the brain parenchyma or cerebral vessels (DeMattos et al., 
2001) (Racke et al., 2005).  This may explain why we see reductions in only the 
diffuse amyloid with the mid domain antibody. These data also suggest that 
clearance of the fibrillar deposits and not diffuse deposits cause the exacerbation 
of CAA, which in this case was only observed with the C terminal antibody.  
Another significant observation from this study was that behavioral 
improvements correlated with antibodies that reduced compact amyloid, 
suggesting that compact amyloid plaques are in some manner associated with 
the memory impairments.  In support of these findings, active immunization with 
Aß of double mutant APP TgCRND8 mice partially prevented the development of 
reference memory deficits in a water maze task, with only a 50% reduction in the 
size and number of dense core amyloid deposits, and no effect on the total 
soluble pool of Aß in brain (Janus et al., 2000). The researchers concluded that 
the prevention of memory deficits was due to the reduced amyloid pathology 
seen in their immunized mice. However, compact deposits are likely to be 
surrounded by a number of smaller, more diffusible, oligomeric assemblies. 
Chronic active immunization had similar beneficial effects on memory impairment 
in two different strains of transgenic mice as assessed using a radial-arm water 
maze (Morgan et al., 2000). Notably, treatment did not affect amyloid pathology 
in the same way in the two strains of mice. Immunized APP+PS1 double 
transgenic mice showed a reduction in diffuse (nonfibrillar) Aß deposits in the 
cerebral cortex and hippocampus, but not in amyloid (fibrillar Aß) deposits. In 
contrast, Tg2576 APP transgenic mice showed a small but statistically significant 
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reduction in cortical amyloid burden, suggesting that active immunization reduces 
the development of fibrillar Aß deposits in this mouse strain. These authors 
concluded that active immunization prevents memory deficits by altering either 
brain amyloid pathology or an unknown pool of non-deposited Aß, perhaps a 
soluble pool of Aß. Lesne and colleagues searched for the appearance of an Aß 
species that coincided with the first observed changes in spatial memory in 6 
month old Tg2576 mice and found that only nonamer and dodecamer (Aß*56) 
levels correlated with impairment of spatial memory (Lesne et al., 2006).  The 
toxic moiety responsible for synaptic dysfunction and neuronal cell loss still 
remains to be identified. Taken together with our data, these results suggest that 
the relationship between soluble and insoluble brain Aß concentrations and 
memory impairment in transgenic mice is complex. One possibility is that in 
young or mid-aged mice, simple removal of soluble Aß species may restore 
learning and memory, yet in old mice, plaque reduction may be more critical. 
Further examination into the redistribution and reduction of different forms of Aß 
will be useful to elucidate what form/s of Aß accompanies the changes in 
memory performance in APP transgenic mice following passive immunization.  
All in all, one antibody failed to produce substantial Aß clearance with 
dramatically less vascular amyloid accumulation. These data suggest that the 
degree of parenchymal Aß clearance determines the extent of vascular Aß 
accumulation. The direct binding of N-terminal antibodies to amyloid-laden 
vessels may aid in the redistribution and removal of parenchymal and vascular 
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Aß respectively but may also exacerbate microhemorrhage by aggravating the 
integrity of the vessel.   
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Figure 1: N- AND C-TERMINAL ANTI-Aß ANTIBODIES IMPROVE COGNITION 
AFTER 12 WEEKS OF TREATMENT. Radial Arm Water Maze mean number of 
errors made over a two day trial period following three months of immunization 
with anti-Aß antibodies directed at different epitopes of the Aß peptide. Each data 
point is the average of three trials. The graph shows the average number of 
errors for APP transgenic mice treated with either N-terminal anti-Aß antibody 
(c, dashed line), Mid-domain anti-Aß antibody (□, dashed line), C-terminal anti-
Aß antibody (U, dashed line), control anti-AMN antibody (■, solid line) and 
nontransgenic mice (●, solid line). * indicates P<0.05 and ** indicates P< 0.01. 
Significance is indicated for both the N-terminal and C-terminal anti-Aß antibody 
treatment groups compared to the group treated with control IgG. 
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Figure 2: TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED BY 
SYSTEMIC ADMINISTRATION OF ANTI-Aß ANTIBODIES. Panels A-F show 
Aß immunohistochemistry from APP transgenic mice in the frontal cortex (Panels 
A, C. E and G) and hippocampus (Panels B, D, F, and H). Mice were treated with 
control anti-AMN antibody (Panels A and B), N-terminal anti-Aß antibody  (Panel 
C and D),  Mid-domain anti-Aß antibody  (Panel E and F), or C-terminal anti-Aß 
antibody  (Panel G and H). F represents the hippocampal fissure. Scale bar in 
panel A = 50µm for all panels. 
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Figure 3: TOTAL Aß IMMUNOHISTOCHEMISTRY IS SIGNIFICANTLY 
REDUCED IN THE FRONTAL CORTEX AND HIPPOCAMPUS AFTER 
SYSTEMIC TREATMENT WITH N-TERMINAL, MID-DOMAIN, AND C-
TERMINAL ANTI-Aß ANTIBODIES. The graph shows the quantification of 
percent area of total Aß staining in the frontal cortex and hippocampus after 12 
weeks of treatment with control IgG, N-terminal (N), Mid-domain (M), and C-
terminal (C) anti-Aß antibodies. Frontal cortex (solid bars); hippocampus (open 
bars). * indicates P<0.05 and ** indicates P<0.01; when compared to mice 
treated with control anti-AMN antibody (CTRL). 
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Figure 4: COMPACT CONGOPHILIC AMYLOID DEPOSITS ARE REDUCED 
BY N- AND C-TERMINAL ANTI-Aß ANTIBODY ADMINISTRATION WHILE 
VASCULAR AMYLOID IS INCREASED. Panels A, C, E, and G show Congo red 
staining in the frontal cortex. Panels B, D, F, and H show Congo red staining in 
the hippocampus. Staining is shown from APP transgenic mice treated with 
control anti-AMN antibody (Panels A and B), N-terminal anti-Aß antibody  (Panel 
C and D), Mid-domain anti-Aß antibody  (Panel E and F), or C-terminal anti-Aß 
antibody  (Panel G and H). Arrows indicate blood vessels positive for vascular 
amyloid, while F reveals the position of the hippocampal fissure. Scale bar in 
panel A = 50µm for all panels. 
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Figure 5: CONGO RED STAINING IN APP TRANSGENIC MICE IS REDUCED 
FOLLOWING TREATMENT WITH N- AND C-TERMINAL ANTI-Aß 
ANTIBODIES.  Panel A shows the quantification of percent area of total Congo 
Red staining in the frontal cortex (solid bars on left) and hippocampus (open bars 
on right) after 12 weeks of anti-Aß antibody passive immunization frontal cortex 
(solid bars) and hippocampus (open bars). Panel B shows quantification of 
parenchymal Congo red in the frontal cortex (solid bars) and hippocampus (open 
bars). Panel C shows quantification of vascular Congo red in the frontal cortex 
(solid bars) and hippocampus (open bars).     * indicates p<0.05, ** indicates 
p<.001 verse control IgG treated mice.  
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Figure 6: THE QUANTIFICATION OF CD45 POSITIVE STAIN REVEALS 
INCREASES AROUND REMAINING DEPOSITS IN THE FRONTAL CORTEX 
AND HIPPOCAMPUS OF APP TRANSGENIC MICE AFTER 12 WEEKS OF C-
TERMINAL ANTI-Aß ANTIBODY ADMINISTRATION. CTRL indicates the anti-
AMN control antibody, N indicates the N-terminal anti-Aß antibody, M indicates 
the mid-domain anti-Aß antibody, and C indicates the C-terminal anti-Aß 
antibody. Panels A and B show the total percent area occupied with positive stain 
for CD45 while panels C and D show calculated ratios of CD45 staining to total 
Congo Red. Panels A and C show quantification in the frontal cortex while panels 
B and D show quantification in the hippocampus. *Indicates P<0.05 and ** 
indicates P<0.01 compared to control. 
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Figure 7: N- AND C-TERMINAL ANTI-Aß ANTIBODIES INCREASE 
MICROHEMORRHAGE LEVELS IN APP TRANSGENIC MICE. The number of 
positive Prussian blue profiles per section was analyzed. CTRL indicates the 
anti-AMN control antibody, N indicates the N-terminal anti-Aß antibody, M 
indicates the mid-domain anti-Aß antibody, and C indicates the C-terminal anti-
Aß antibody. ** indicates P<0.01 verse APP transgenic mice treated with control 
IgG. 
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ABSTRACT 
 
 The accumulation of ß-amyloid in Alzheimer’s disease is a key 
pathological event. However, the reason for the accumulation is unclear. Aß 
accumulation can be described by two hypotheses, the Accumulation hypothesis 
or the Equilibrium hypothesis. The accumulation hypothesis suggests that Aß 
deposition is a result of production slightly exceeding clearance mechanisms 
leading to a gradual accumulation of the excess Aß in the brain. The equilibrium 
hypothesis suggests that the rate of Aß production, degradation and excess is in 
a steady state equilibrium. The increase with age results from equilibrium 
dynamics. This study was designed to investigate the extent to which the level of 
Abeta in brain is due to passage of time versus a change in production/clearance 
with age. We accomplished this experiment by passively immunizing Tg2576 
mice with anti-Aß antibodies (2H6), starting at an age when amyloid deposition 
first begins (8 months) and ending treatment 6 months later at an age when 
untreated Tg2576 mice have considerable amounts of deposited amyloid. We 
then monitored the progression of amyloid accumulation over the next 3 mo in 
the two groups to ascertain if the suppressed group would “catch up” to the 
untreated group (equilibrium) or if it would remain suppressed (accumulation).  
 We found that the anti-Aß 2H6 antibody successfully suppressed the 
deposition of Aß after 6 months of treatment. We also found that 3 months after 
the cessation of treatment with anti-Aß 2H6, diffuse and compact Aß deposits as 
well as markers of microglial activation, remained significantly reduced compared 
to the Tg2576 mice that received control IgG.   These results suggest that Aß 
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deposition occurs because production mechanisms exceed clearance 
mechanisms by a small amount, and the excess becomes converted to a form 
that deposits and builds up in a time dependent manner. 
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INTRODUCTION 
 
Aß is continuously produced from the ßAPP in brains of normal subjects 
and patients with AD.  By some undefined mechanism, Aß deposits accumulate 
in the brains of patients developing AD.  This observable fact is mimicked in APP 
transgenic mouse models (Games et al, 1995) (Hsiao et al, 1996),despite 
stability of transgene expression (Johnson-Wood et al., 1997).  Aß40 & 42 
accumulates with age, first as diffuse plaques lacking glial changes and later as 
fibrillar, thioflavin-S positive neuritic/glial plaques (Selkoe, 2001). Deposition of 
Aß42 is believed to precede that of Aß40 in the brain, which is supported by in 
vitro studies that show Aß42 can aggregate more readily (Jarrett et al., 1993); 
(Iwatsubo et al., 1994).   
Aß plaques are thought to be formed from the gradual accumulation and 
aggregation of secreted Aß in the extracellular space. This statement is 
consistent with the accumulation hypothesis which suggests that Aß deposition is 
a result of production exceeding clearance mechanisms by a small amount, and 
the excess becomes converted to a form that deposits and builds up in a time-
dependent manner (Maggio et al., 1992); (Prior et al., 1996). The accumulation 
hypothesis might indicate that treatments reducing Aß production or increasing 
soluble Aß clearance might prevent further Aß deposition, but would not remove 
existing deposits (this would require clearing fibrillar deposits).  
Another possible explanation for increasing levels of Aß in the brain is that 
steady-state disequilibrium exists between anabolic and catabolic activities.  The 
equilibrium hypothesis suggests that the rate of Aß production, degradation and 
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removal is altered with age, and that the different pools of Aß are to some extent 
exchangeable; removal of one pool will ultimately lead to removal of the others.  
Insulin degrading enzyme (IDE) and neprilysin, two proteases that degrade Aß, 
have age related reductions in steady-state levels in regions of the brain with 
amyloid deposition (Caccamo et al., 2005), (Iwata et al., 2002).   
In this study, we developed a scheme to evaluate why aberrant Aß 
accumulation occurs by assessing whether Aß deposition is a factor of 
accumulation over time (Accumulation Hypothesis) or is triggered by changes in 
the brain microenvironment with age (Equilibrium Hypothesis). We accomplished 
this by delaying deposition using passive immunization with anti-Aß antibodies 
between the ages of 7-14 months (Tg2576 mice typically start depositing Aß at 8 
months of age.) We then released the suppression and evaluated the pathology 
3 months later.  
 
MATERIALS AND METHODS 
Experimental Design. All APP Tg2576-derived mice were bred in our facility at 
the University of South Florida and genotyped using previously described 
methods (Holcomb et al., 1998); (Gordon et al., 2002).  Importantly, we have 
intentionally bred out the retinal degeneration 1 mutation from this colony to 
avoid the inclusion of occasional mice that are blind due to homozygous 
inheritance of this mutation contributed by the SJL/J background (Alamed et al., 
2006). Fourteen eight month old Tg2576 mice were injected with the anti-Aß 
antibody, 2H6 (Aß33-40 Ig2b; Rinat Neurosciences, South San Francisco, CA), for 
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6 months at a concentration of 10mg/kg weekly (i.p.) until they reach 14 months 
of age, at which time we ended injections. At this point we euthanatized the mice 
at 1 day and 12 weeks post treatment.  A group of 14 Tg2576 mice received 
weekly injections of control antibody directed against the drosophila specific 
amnesiac protein (2908, mouse monoclonal anti-drosophila amnesiac protein 
IgG2b; Rinat Neurosciences, South San Francisco, CA). These control APP 
transgenic mice underwent the same treatment and euthanization schedule as 
the mice treated with the 2H6 antibody.   
 
Tissue Preparation. On the day of sacrifice the mice were overdosed with 100 
mg/kg of Nembutal sodium solution (Abbott laboratories, North Chicago IL). The 
mice were perfused intracardially with 25 ml of 0.9% saline. The right brain 
hemisphere was dissected and stored for later analysis. These tissues were 
rapidly frozen on dry ice and stored at -80oC.  The left hemisphere was removed 
and immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours, then 
passed through 10, 20 and 30% sucrose solutions for 24 hours each.  
 
Histology. Horizontal sections of 25μm thickness were collected using a sliding 
microtome and stored in DPBS + azide. A series of 8 sections spaced 
approximately 600μm apart were stained immunohistochemically using the free-
floating method for total Aß (rabbit polyclonal anti-Aß, generously provided by 
Paul E. Gottschall, USF, FL 1:10000) to determine the amount of diffuse Aß, as 
previously described (Gordon et al., 2002). Additional sections were 
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immunostained for various microglial markers associated with different stages of 
amyloid deposition.  Complement receptor 3 (CD11b) (rat monoclonal anti-
CD11b, Serotec, Raleigh, NC 1:3000) is associated with the earliest deposits in 
young mice, CD45 (rat monoclonal anti-CD45, Serotec, Raleigh, NC 1:3000) is 
an intermediate marker, and MHC-II (rat monoclonal anti-I-A/I-E, BD Pharmingen 
1:3000) is a marker associated with deposits in older mice (Gordon et al., 2002). 
Adjacent sections were stained with 0.2% Congo red solution in NaCl saturated 
80% ethanol, which detects the compact amyloid plaques made of up fibrillar Aß.   
Quantification of the histological markers was performed using the Image-
Pro Plus (Media Cybernetics, Silver Spring, MD) software to analyze the percent 
area occupied by positive stain. Two regions of the cortex and three regions of 
the hippocampus were analyzed (to ensure that there was no regional bias in the 
values). To assess possible treatment-related differences in pathology, the 
histochemical values for each treatment group were analyzed by one-way 
ANOVA followed by Fischer’s LSD means comparisons using StatView (SAS 
Institute Inc, NC). 
 
Abeta ELISA.  Tissue homogenization and extraction: Microdissected frontal 
cortices from one hemisphere were sequentially extracted with buffers designed 
to increasingly solubilize amyloid deposits.  At each step, homogenization, (30 
seconds) in an appropriate buffer (150mg/ml wet weight) which contained 
protease inhibitors (complete mini protease inhibitor cocktail; Roche) was 
followed by centrifugation at 100,000 X g for 1 hr at 4°C. The supernatant was 
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then removed and the pellet was homogenized in the next solution used in the 
extraction process.  The extraction took place first in Tris-buffered saline (TBS) 
(20mM Tris, 137 mM NaCl, pH 7.6), and the resultant pellet was then extracted 
with SDS diluted with TBS to a final concentration of 2%, and the resultant pellet 
was then extracted with 70% formic acid (FA) diluted with TBS.  Aß1-40 and Aß1-42 
was quantified in these samples using individual Aß1-40, 1-42 ELISA kits (Signet, 
Berkeley, CA) in accordance with the instructions of the manufacturer, except the 
standards included dilutions of 2%SDS or 70% formic acid when necessary.  
 
Western Blot.  Posterior cortices were placed in 300µl ice cold cell lysis 
buffer with protease inhibitors (Cell Signaling Technology, Danvers MA). The 
brains were then homogenized for 30 seconds followed by a 30 second 
sonication.  Total protein content was assessed using the Bio-Rad Protein assay 
kit according to the manufacturer’s instructions. A 50 µg aliquot of total protein 
from each sample was diluted in 4X SDS loading buffer (each 100 ml of buffer 
contains: 3 g Tris; 8 g SDS; 2.5 g DTT; 0.05 g Bromophenol blue; 40% [v:v] 
glycerol) and electrophoretically separated using 4-20% tris-glycine gels at 80v 
for 2 hours. Electrophoresed proteins were then transferred to polyvinylidene 
difluoride membranes (Bio-Rad, Richmond, CA), washed in 1x Tris-buffered 
saline with 20% tween (TBS-T) three times, and blocked for 1 hour at room 
temperature with BlockerTM BLOTTO in TBS (Pierce, Rockford, IL). After 
blocking, the membranes were hybridized over night at 4°C with various primary 
antibodies.  The primary antibodies included the APP C-terminal 751-770 
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antibody (Calbiochem, San Diego, CA), BACE-1 (gifted from Dr.Vassar and Dr. 
Binder), and GAPDH (Biodesign International, Saco, ME). The membranes were 
washed three times with TBS-T and incubated for 1 hour at room temperature 
with the appropriate HRP-conjugated secondary antibody. All antibodies were 
diluted with BlockerTM BLOTTO. Immunoreactive bands were detected by 
LumiGold ECL western blotting detection kit (Ver II) (Signagen Laboratories, 
Gaithersburg, MD) according to the manufacturer's instruction and then exposed to 
film which was developed for later densitometric analysis. All membranes are re-
probed (without stripping) with anti-GAPDH to control for equal protein loading in 
each lane. Bands were quantified using Scion Image (NIH, Bethesda, MD) by 
analyzing pixel density. Semiquantitative analysis was performed by 
densitometry, correcting protein levels for GAPDH. 
 
RESULTS 
 To study the deposition of Aß we used transgenic mice containing a 
double mutation, K670N and M671L, in the human APP gene under the control 
of a hamster prion promoter (Tg2576; Hsiao et al., 1996). The primary dependent 
measure in this study was Aß deposition.  Hypothetical outcomes depicting the 
percent area of total Aß deposition according to the Accumulation hypothesis or 
the Equilibrium hypothesis are shown in Figures 1A and B respectively. If the 
outcome were to support the accumulation hypothesis, we would expect to see, 
once suppression is released, the slope of the lines for both the control and 
treated groups to be the same but shifted to the right (delayed) for the mice 
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whose amyloid deposition was suppressed with 2H6 for 6 months (Fig 1A). If the 
outcome were to support the equilibrium hypothesis, we would expect to observe 
a rapid elevation of Aß load following the release of suppression in the mice 
treated with 2H6. The rapid elevation in Aß load would near the control 
transgenic mice amyloid levels within 1-2 months (Figure 1B). This type of 
outcome would indicate that the environment of the aging brain was determining 
the amount of Aß deposited.  The hypothetical and actual results are based upon 
histological observations at 3 time points; 8 months of age (the age at which 
Tg2576 mice begin to deposit), 14 months of age (the time at which suppression 
of Aß deposition with 2H6 is released), and 17 months of age (3 months post-
treatment).  
 After systemic treatment with anti-Aß antibodies for 6 months, we 
observed that antibody administration prevented Aß deposition and substantially 
delayed the deposition of amyloid (Figure 2). Total Aß immunohistochemistry in 
the Tg2576 mice that received the control antibody showed several intensely 
stained deposits along with numerous diffuse deposits in the frontal cortex 
compared to the age-matched transgenic mice that received the 2H6 antibody 
(Figure 2A & B). The mice that received the control antibody demonstrated the 
typical amount and distribution of Aß for Tg2576 mice at these age points with a 
5-fold increase in total Aß between the ages of 14 and 17 months; with an 
average value of 15% of the frontal cortical area being littered with amyloid by 
the age of 17 months. (Figure 2E) (Hsiao et al., 1996) (Kawarabayashi et al., 
2001). The mice treated with 2H6 showed a significant suppression of amyloid 
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deposition at the 14 month time point (Figure 2C). The total Aß 
immunohistochemistry showed very few compact deposits as well as very sparse 
diffuse Aß stain which encompassed less than 1.5% area of the frontal cortex 
(Figure 2C & E). Three months after treatment was stopped, the total percent 
area of Aß was 6% in the frontal cortex of mice that had been previously treated 
with 2H6. The Aß percent area from the 17 month 2H6 group resembled the 
percent area from the 14 month old control group (Figure 2E). Nonetheless, 
treatment with 2H6 antibody for 6 months resulted in significant reductions in 
total Aß immunohistochemistry in the frontal cortex and these significant 
reductions were maintained 3 months after treatment was stopped. 
 Congo red staining detects compact amyloid deposits in the ß-pleated 
sheet formation.  There are far fewer Congo red positive deposits than Aß 
deposits detected by total Aß immunohistochemistry.  Compared to the mice that 
received control antibody; the mice treated with 2H6 showed significantly less 
compact deposits in the frontal cortex at the 14 month time point (Figure 3A,& C). 
Three months after the release of suppression, these mice continued to show 
significant reductions (approximately 50%) in compact amyloid (Figure 3E).  
 In addition to Aß amyloid histology, we immunohistochemically stained for 
microglial markers that correlate to various levels of activation; complement 
receptor 3 (CD11b), CD 45, and MHC-II. Complement-receptor 3 expression was 
increased around the earliest Congophilic deposits in young mice. CD 45 is a 
protein-tyrosine phosphatase and is expressed at intermediate stages of Aß 
deposition.  MHC-II is a marker that is expressed around mature deposits in older 
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mice (Gordon et al., 2002). In this study, we did not see any differences in 
complement-receptor 3 expression between the control and treated groups at the 
14 or 17 month age points (Data not shown). We also did not find differences in 
MHC-II immunohistochemistry between control and treated groups. In fact we 
rarely observed positive MHC-II microglia at the 14 or 17 month time points (Data 
not shown).  
 CD 45 expression increases at an intermediate stage of plaque 
maturation. At the 14 month time point, CD 45 expression is extremely low in 
both the treated and control group (Figure 4A & C). However, we observed a 
significant increase in CD45 expression on microglia surrounding amyloid 
deposits in the frontal cortex of the control group at the 17 month time point 
(Figure 4B). Three months after the treatment was stopped, the 17 month old 
2H6 group CD45 expression resembled the 14 month control group expression 
levels (Figure 4E). The CD 45 expression time course resembled the total Aß 
time course, where the control group demonstrated an accelerated increase in 
expression between14 and 17 months of age and the treated group showed a 
slight increase in this period of time with the endpoint resembling the 14 month 
untreated group levels.  
 To confirm the histological findings, anterior cortex homogenates from the 
contralateral side of the brain were extracted sequentially in TBS, 2% SDS, and 
70% formic acid and measured for Aß40 and Aß42 levels with sandwich ELISAs.  
Sequential extractions allowed measurement of different pools of Aß.  The TBS 
fraction represented the most soluble fraction. Tg2576 mice at 14 to 17 months 
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of age have small amounts of TBS-soluble Aß (Kawarabayashi et al., 2001). 
Most Aß requires SDS or formic acid for solubilization since the most abundant 
form of Aß at these ages are the insoluble, fibrillar forms (Kawarabayashi et al., 
2001). In both Aß40 and Aß42 ELISAs, the greatest concentration of Aß was 
found in the SDS extraction.  The ELISAs confirmed the changes found with the 
histological markers.  Significant reductions were found in the levels of both Aß40 
and Aß42 in the transgenic mice treated with 2H6 at the 14 month time point 
(Figure 5A & B). These significant reductions were maintained 3 months after 
treatment was stopped. Interestingly, the 2H6 antibody directed against Aß33-40 
was able to reduce Aß42.  
 To ensure that long-term antibody treatment did not alter APP processing, 
we measured steady state levels of APP and BACE in posterior cortex 
homogenates by western blot analysis.  We found that the holo-APP protein 
levels were unaltered with age or treatment (Figure 6A &B).  BACE-1 levels, 
however, increased with age but treatment did not alter these levels (Figure 6A & 
C).  A recent observation in Tg2576 mice found that BACE-1 expression 
increased with age in Tg2576 mice (Zhao et al., 2007). In addition to holo-APP 
and BACE-1, we measured α-CTFs and ß-CTFs and found no significant 
changes with treatment or age (data not shown).  
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DISCUSSION 
 This study was designed to investigate the extent to which changes in the 
brain environment with aging regulate the extent of amyloid deposition. The 
process of amyloid deposition in the brain can be explained by one of two 
hypotheses, the accumulation hypothesis or the equilibrium hypothesis. The 
accumulation hypothesis suggests that deposition of Aß is a time-dependent 
process, while the equilibrium hypothesis suggests that deposition is a factor of 
the brain microenviroment. We attempted to discriminate between these two 
options by passively immunizing Tg2576 mice with anti-Aß antibodies (2H6), 
starting at an age when amyloid deposition first begins (8 months) and ending 
treatment 6 months later at an age when control Tg2576 mice have considerable 
amounts of deposited amyloid. In order to evaluate the pattern of amyloid 
deposition, we allowed 3 months post-treatment for amyloid to deposit in these 
mice. There were two major observations taken from this study.  
 The first major observation is that the data confirm that passively 
administered anti-Aß antibodies reduce or prevent Aß deposition in Tg2576 mice. 
Previous studies have shown that anti-Aß immunization prevents amyloid 
deposition in young PDAPP mice (Schenk et al., 1999). The 
immunohistochemical data plotted for the 14 month time point depicts the 
percent area of Aß pathology found in the frontal cortex of Tg2576 after 6 months 
of treatment with 2H6 antibodies compared to control transgenic mice. We found 
that treatment with the 2H6 antibody caused significant reductions in total and 
compact Aß as measured with anti-Aß immunohistochemistry and Congo red.  
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We did not find significant reductions in CD45 expression at the 14 month time 
point because the total expression of CD45 is very low in both groups at 14 
months of age.  In addition to histopathological findings, biochemical 
quantification of Aß40 and Aß42 with ELISAs showed significant reductions in 
the treated group at the 14 month time point.  
The second and principal observation taken from this study is that the 
deposition of amyloid and microglial activation never reached the levels found in 
the control transgenic group.  In fact, Aß pathology was delayed in the mice 
treated with 2H6 compared to the mice treated with control antibody. The data 
plotted for the 17 month time point portrays the percent area of AD pathology 
found in the frontal cortex of Tg2576 mice 3 months after the cessation of 
antibody treatment. The control transgenic mice displayed accelerating increases 
in both diffuse and compact amyloid pathology, as well as microglial expression 
between the 14 and 17 month data points. Tg2576 mice that received control 
antibody exhibited a five-fold increase in total Aß between 14 and 17 months of 
age; with an average value of 15% of the frontal cortical area being littered with 
amyloid by the age of 17 months, while the total percent area of Aß was only 6% 
in the frontal cortex of the 17 month old mice that had been previously treated 
with 2H6. In addition to total Aß, we found that the percent area of Congo red 
positive plaques was two-fold less in the mice previously treated with 2H6 at the 
17 month time point compared to the control transgenic mice.  At the 17 month 
time point, the control transgenic mice had a 3-fold higher expression of activated 
microglia in the frontal cortex than the suppressed mice.  Aß40 and Aß42 specific 
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ELISAs confirm these findings and show up to two-fold less Aß in the 17 month 
old mice that had been treated with 2H6. Essentially, these data suggest that 
delayed deposition of amyloid lead to long term delays in AD associated 
pathology because steady state levels of brain amyloid are controlled less by the 
brain microenvironment and more by deposition over time. 
 Several reports have supported the concept of the equilibrium hypothesis 
and have demonstrated a rapid return of Aß levels to control transgenic levels 
following an intracranial treatment.  Our work previously showed that intracranial 
administration of LPS resulted in rapid clearance of diffuse Aß that returned to 
control levels by 3 weeks (Herber et al., 2004).  Intracranial injections of anti-Aß 
antibodies rapidly cleared 50% or more of deposited amyloid, yet resulted in 
rapid return towards control levels (Chauhan et al., 2004) (Oddo et al., 2004). In 
addition to these studies, there are several anomalies found with anti-Aß 
immunotherapy that would suggest that amyloid plaques are rather pliable and 
support the equilibrium hypothesis. For example, antibodies directed against the 
40 amino acid length Aß peptide result in the clearance of both Aß40 and Aß42 
(Levites et al., 2006).  Our data support the findings by Levites and colleagues as 
shown with the Aß ELISA results in Fig 5.  The 2H6 antibody used in our study is 
selective for the 40 amino acid length Aß peptide yet significantly clears Aß42.  
Antibodies generated against Aß in the human Elan trials were composed almost 
exclusively of N-terminal anti-Aß antibodies, yet ultimately the serum cleared 
both intact and N-terminally truncated Aß (Nicoll, James AD/PD Salzburg 
Meeting March 2007).  
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Based on the results described above, we anticipated that the equilibrium 
hypothesis would be at least partially responsible for the observed accumulation 
of amyloid with age.  However, there are several differences between our study 
design and the studies that show a rapid return in amyloid levels after treatment.  
One major difference is the age of the animals at the time of treatment.  All of the 
mice used in these studies that support the rapid return of Aß plaque had 
abundant plaque deposition at the time of treatment.  We purposely chose a 6 
month treatment regimen starting on Tg2576 mice at 8 months to prevent the 
deposition of amyloid plaque.  We assume that we were not only able to prevent 
the deposition of amyloid but also prevented the production of Aß "seeds", 
analogous to nucleation centers for crystal formation.  
The accumulation of Aß is hypothesized to depend on preexisting seeds 
to recruit more Aß and form plaques. Growth of the fibrils occurs by assembly of 
the Aß seeds into intermediate protofibrils, which in turn self-associate to form 
mature fibers. Fibrillogenesis is a two-step reaction involving an initial slow, lag 
period that reflects the thermodynamic barrier to the formation of a nucleation 
“seed” followed by a rapid fibril propagation and aggregation stage (Jarrett and 
Lansbury, Jr., 1993). The C-terminal region of the Aß peptide, amino acids 29-
40/42, contributes to the key ß-sheet structure as well as fibril assembly via side-
chain interactions (Kirschner et al., 1987). This region is also important for the 
structural transition and the stability of Aß fibrils. The anti-Aß 2H6 antibody 
targets the C-terminal end of Aß and may interfere with the precursor pool that is 
responsible for the aggregation of Aß, thus resulting in a more effective 
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prevention. It would be interesting to see if anti-Aß antibodies directed against 
other epitopes of Aß would result in similar accumulation patterns after cessation 
of treatment. 
The accumulation hypothesis indicates that treatments reducing Aß 
production or increasing soluble Aß clearance might prevent further Aß 
deposition, but would not remove existing deposits, especially the forms 
composed of multimeric complexes, such as fibrillar deposits with associated 
neuritic dystrophy and glial activation. Jankowsky and colleagues (2005) created 
a mouse that overexpresses mutant APP from a vector that is regulated by 
doxycycline (Jankowsky et al., 2005). Under normal conditions, this mouse 
model develops Aß pathology. Administration of doxycycline suppresses the 
mutant APP expression up to 95%, and essentially turns off the production of Aß. 
In this particular experiment, doxycycline was administered after the onset of 
amyloid pathology. The result of the suppression caused by doxycycline halted 
the progression of amyloid pathology; however, existing plaques remained 
(Jankowsky et al., 2005). Based upon our data and data from Jankowsky and 
colleagues, amyloid deposits appear to require far longer to disperse than to 
assemble (Jankowsky et al., 2005).  We interpret our findings as evidence that 
AD therapies that alter the production of Aß by inhibiting secretase activity or 
inhibiting APP expression may not quickly reverse preexisting pathology. These 
data strongly support the use of prophylactic treatments, as it appears that 
amyloid deposits will require interventions that actively clear amyloid as the only 
means to efficiently reduce brain Aß in AD.  
 95
 
REFERENCE LIST 
 
Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D (2006) Two-day 
radial-arm water maze learning and memory task; robust resolution of amyloid-
related memory deficits in transgenic mice. Nat Protoc 1: 1671-1679. 
Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and 
region-dependent alterations in Abeta-degrading enzymes: implications for 
Abeta-induced disorders. Neurobiol Aging 26: 645-654. 
Chauhan NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer's 
disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci 
Res 69: 10-23. 
Chauhan NB, Siegel GJ, Lichtor T (2004) Effect of age on the duration and 
extent of amyloid plaque reduction and microglial activation after injection of anti-
Abeta antibody into the third ventricle of TgCRND8 mice. J Neurosci Res 78: 
732-741. 
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr 
T, Clemens J, Donaldson T, Gillespie F, . (1995) Alzheimer-type neuropathology 
in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 
373: 523-527. 
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor 
K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time course of the 
development of Alzheimer-like pathology in the doubly transgenic PS1+APP 
mouse. Exp Neurol 173: 183-195. 
Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN 
(2004) Time-dependent reduction in Abeta levels after intracranial LPS 
administration in APP transgenic mice. Exp Neurol 190: 245-253. 
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, 
Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada 
CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type 
phenotype in transgenic mice carrying both mutant amyloid precursor protein and 
presenilin 1 transgenes. Nat Med 4: 97-100. 
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole 
G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in 
transgenic mice. Science 274: 99-102. 
Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC (2002) Region-specific 
reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus 
upon aging. J Neurosci Res 70: 493-500. 
 96
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) 
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A 
beta monoclonals: evidence that an initially deposited species is A beta 42(43). 
Neuron 13: 45-53. 
Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, 
Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR (2005) 
Persistent amyloidosis following suppression of Abeta production in a transgenic 
model of Alzheimer disease. PLoS Med 2: e355. 
Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The carboxy terminus of the beta 
amyloid protein is critical for the seeding of amyloid formation: implications for the 
pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697. 
Jarrett JT, Lansbury PT, Jr. (1993) Seeding "one-dimensional crystallization" of 
amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 
1055-1058. 
Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon 
M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) 
Amyloid precursor protein processing and A beta42 deposition in a transgenic 
mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94: 1550-1555. 
Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) 
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the 
Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381. 
Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ (1987) Synthetic 
peptide homologous to beta protein from Alzheimer disease forms amyloid-like 
fibrils in vitro. Proc Natl Acad Sci U S A 84: 6953-6957. 
Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE 
(2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid 
beta, amyloid beta40, and amyloid beta42 single-chain variable fragments 
attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26: 
11923-11928. 
Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna 
SR, Vinters HV, Labenski ME, Mantyh PW (1992) Reversible in vitro growth of 
Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid 
peptide. Proc Natl Acad Sci U S A 89: 5462-5466. 
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta 
immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau 
aggregates via the proteasome. Neuron 43: 321-332. 
 97
Prior R, D'Urso D, Frank R, Prikulis I, Cleven S, Ihl R, Pavlakovic G (1996) 
Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile 
plaques. Am J Pathol 148: 1749-1756. 
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, 
Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, 
Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, 
Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta 
attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 
173-177. 
Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 
81: 741-766. 
Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron 
M, Berry R, Binder L, Vassar R (2007) Beta-site amyloid precursor protein 
cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: 
implications for Alzheimer's disease pathogenesis. J Neurosci 27: 3639-3649. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98
 
Figure 1. THEORETICAL INTERPRETATION OF ABETA ACCUMULATION 
BASED ON THE PERCENT AREA OF TOTAL Aß IMMUNOHISTOCHEMISTRY 
AT 3 AGE POINTS; 8, 14, AND 17 MONTHS. The solid line in the figure 
represents the control group Aß levels, and the dashed line represents the group 
treated with 2H6 for 6 months.  A. Represents the accumulation hypothesis. B. 
Represents the equilibrium hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99
Figure 2. TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED FOLLOWING 
6 MONTHS OF SYSTEMIC ANTI-Aß ANTIBODY ADMINISTRATION. Panels A 
& B show total Aß immunohistochemistry in the frontal cortex of Tg2576 mice 
that received control antibody at 14 months of age and at 17 months of age 
respectively. Panel C & D show total Aß immunohistochemistry in Tg2576 mice 
that received anti-Aß antibody at 14 months of age and at 17 months of age. 
Scale bar 1cm = 50µm. Panel E shows quantification of the percent area 
occupied by Aß positive stain in the frontal cortex. The solid line shows the value 
for APP transgenic mice that received control antibody. The dotted line shows 
the values for APP transgenic mice that received anti-Aß antibody. ** indicates 
P<0.01.  
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Figure 3. CONGO RED HISTOCHEMISTRY REPRESENTING COMPACT 
AMYLOID DEPOSITS ARE REDUCED AFTER 6 MONTHS OF SYSTEMIC 
ANTI-Aß ANTIBODY ADMINISTRATION AND THESE REDUCTIONS ARE 
MAINTAINED 3 MONTHS AFTER THE CESSATION OF TREATMENT.  
Panels A & B show Congo red histochemistry in the frontal cortex of Tg2576 
mice that received control antibody at 14 months of age and at 17 months of age. 
Panel C & D show Congo red histochemistry in Tg2576 mice that received anti-
Aß antibody at 14 months of age and at 17 months of age. Scale bar 1cm = 
50µm. Panel E shows quantification of the percent area occupied by Congo red 
positive plaques in the frontal cortex. The solid line shows the value for APP 
transgenic mice that received control antibody. The dotted line shows the values 
for APP transgenic mice that received anti-Aß 2H6 antibody. ** indicates P<0.01.  
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Figure 4. CD 45 EXPRESSION IS REDUCED AFTER 6 MONTHS OF 
SYSTEMIC ANTI-Aß ANTIBODY ADMINISTRATION AND THESE 
REDUCTIONS ARE MAINTAINED 3 MONTHS AFTER THE CESSATION OF 
TREATMENT. Panels A & B show CD 45  immunohistochemistry in the frontal 
cortex of Tg2576 mice that received control antibody at 14 months of age and at 
17 months of age respectively. Panel C & D show CD 45 immunohistochemistry 
in Tg2576 mice that received anti-Aß antibody at 14 months of age and at 17 
months of age. Scale bar 1cm = 50µm. Panel E shows quantification of the 
percent area occupied by Congo red positive plaques in the frontal cortex. The 
solid line shows the value for APP transgenic mice that received control antibody. 
The dotted line shows the values for APP transgenic mice that received anti-Aß 
antibody. ** indicates P<0.01.  
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Figure 5. ELISA MEASUREMENTS OF Aß40 AND Aß42 AFTER EXTRACTION 
IN TBS, SDS, AND FORMIC ACID FROM THE ANTERIOR CORTEX OF 
TG2576 MICE FOLLOWING 6 MONTHS OF PASSIVE IMMUNIZATION WITH 
EITHER CONTROL IGG OR ANTI-Aß ANTIBODY 2H6. Panel A represents the 
stacked total of Aß40 in 14 and 17 month old Tg2576 mice treated with either 
control IgG or anti-Aß 2H6. Panel B represents the stacked total of Aß42 in 14 
and 17 month old Tg2576 mice treated with either control IgG or anti-Aß 2H6. 
* represents p< 0.05 for the stacked averages consisting of the 3 extractions in 
mice treated with 2H6 compared to mice treated with control IgG. 
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Figure 6. WESTERN BLOT ANALYSIS OF HOLO APP & BACE-1 IN 14 AND 
17 MONTH OLD TG2576 MICE THAT RECEIVED CONTROL IGG OR ANTI-Aß 
2H6. The blots for APP and BACE-1 are shown in panel A for posterior cortex. 
Panel B & C show the quantification of western blots for APP and BACE-1. The 
levels for each time point were adjusted to the relative GAPDH levels, which 
were used as a protein loading control.    
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CONCLUSIONS 
Alzheimer’s disease (AD) is the most common cause of age-related 
dementia with a prevalence approaching 40 to 50% by age 80. At present, 4 
million Americans are affected with AD at an estimated annual care cost of 
almost 100 billion dollars. The number of individuals 65 years and older is 
growing rapidly due to an increase in the general average life expectancy.  As a 
result, it is estimated that the total incidence of AD will quadruple by the year 
2050 (Hebert et al., 2003).  Therefore, it is urgent to find a means of preventing, 
delaying the onset, or reversing the course of AD.  
The presence of high densities of neuritic plaques composed of Aß in the 
cerebral cortices is a criterion for the post-mortem diagnosis of AD. The view that 
Aß deposition drives the pathogenesis of AD (amyloid hypothesis) has received 
support from a wide range of molecular, genetic, and animal studies (Selkoe, 
2001). The first form of evidence came from the localization of the APP gene to 
chromosome 21. AD-like neuropathology is invariably seen in Down’s syndrome, 
and results from increased APP expression and consequent higher Aß levels 
(Mann et al., 1984) (Glenner and Wong, 1984). Previous studies have shown that 
synthetic Aß peptides are neurotoxic to hippocampal and cortical neurons, both 
in culture and in vivo (Pike et al., 1993) (Lambert et al., 1998) (Deshpande et al., 
2006). Inherited mutations in the APP gene occur within the Aß region and alter 
the amount or aggregation properties of Aß and are sufficient to cause early-
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onset AD (Goate et al., 1991) (Levy et al., 1990). In addition to the APP gene, 
inherited mutations within the presenilin 1 and 2 genes increase the Aß42/40 
ratio and cause early forms of AD (Kumar-Singh et al., 2006).  The discovery of 
these mutations has allowed for the development of mice transgenic for mutant 
human APP. These APP mutant mice show a time-dependent increase in 
extracellular Aß and develop certain neuropathological and behavioral changes 
similar to those seen in AD (Hsiao et al., 1996) (Games et al., 1995).  
The amyloid cascade hypothesis has been a driving factor in the field of 
AD therapeutics and has led to the development of drugs which target the 
production and clearance of Aß; one such approach is immunotherapy. Since the 
first report that active immunization with fibrillar Aß42 in PDAPP transgenic mice 
prevented the development of amyloid plaques, neuritic dystrophy, and 
astrogliosis (Schenk et al., 1999), there have been a plethora of data published 
from studies conducted on APP transgenic mice and humans regarding the use 
of both active and passive immunization for the treatment of AD.  Although there 
is still no consensus on how Aß immunotherapy works, the data thus far have 
given us insight into possible mechanisms of action of antibody mediated Aß 
removal from the brain while unveiling adverse effects such as cerebral amyloid 
angiopathy (CAA) and microhemorrhage.  
Passive immunization has allowed scientists to examine the in vivo 
binding properties, pharmacokinetics, brain penetrance, and changes in Aß 
levels after peripheral administration.  The average half-life of a monoclonal 
antibody (mAb) in mouse plasma has been reported to be ~1 week (Vieira and 
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Rajewsky, 1986). After an intraperitoneal injection, no more than 50% of the 
monoclonal anti-Aß antibody is bioavailable in the plasma (Levites et al., 2006).  
Once in the plasma, the anti-Aß antibodies bind circulating Aß.  We and many 
others demonstrated that twenty-four hours after anti-Aß antibody administration, 
both Aß40 and Aß42 significantly increase in serum. (DeMattos et al., 2002) 
(Wilcock et al., 2004b) (Levites et al., 2006) (Paper 1).   
Antibody administration may clear brain Aß without the mAb actually 
entering the brain. When mAbs directed against the central domain of Aß were 
peripherally administered to 3 month old PDAPP mice, the result was a rapid 
1000 fold increase in plasma Aß and reductions in amyloid burden in the brain.  It 
is thought that the antibody sequestered plasma Aß, which disrupted the 
equilibrium of Aß in the CNS and plasma, causing an efflux of Aß out of the brain 
into the periphery (DeMattos et al., 2002).  
However, here we show in paper 1, evidence which would appear to 
contradict the peripheral sink mechanism. In a deglycosylated anti-Aß dose 
response study, we show that the highest dose of 30 mg/kg was able to 
sequester the most Aß in the serum while the intermediate dose 10 mg/kg and 
lowest dose of 3 mg/kg sequestered intermediary and smaller Aß levels, 
respectively (Paper 1; Figure 1). If the peripheral sink mechanism were playing a 
major role in Aß clearance from the brain, one would predict the greatest 
reductions in Aß would occur with the highest dose.  Yet in fact, we found the 
exact opposite.  The lowest dose cleared the most diffuse and compact Aß from 
the brain while the highest dose failed to significantly reduce amyloid levels 
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compared to mice treated with control IgG.  Therefore, changes in serum Aß 
levels do not show a relationship with reductions in brain Aß in APP transgenic 
mice after systemic treatment with anti-Aß antibodies.  
A possible explanation for these results may be that the passively 
administered anti-Aß antibodies bind already circulating Aß.  Previous studies 
have established that Aß has a very short half-life in the plasma. When free Aß is 
injected intravenously into mice, it is cleared within 10 minutes (Ghiso et al., 
2004). However, peripheral administration of anti-Aß antibodies creates a stable 
mAb:Aß complex in the plasma and the complex is cleared slowly. The antibody 
bound Aß has a half-life of 5-7 days (Levites et al., 2006).  Thus the rapid rise in 
plasma Aß observed is attributable to prolongation of the half-life of Aß bound to 
antibody.  This phenomenon may be unique to APP transgenic mice since the 
over expression of APP and the accumulation of Aß are not specific to the CNS 
but also occur in several organ systems (Kawarabayashi et al., 2001).  APP 
transgenic mice have higher endogenous circulating Aß levels than humans. 
Therefore, one might not observe the spike in plasma Aß following immunization 
in humans (Kawarabayashi et al., 2001), as reported by Hock et al (2002).  
A small fraction of anti-Aß antibodies can penetrate the BBB; when 
quantified these levels were <0.1% of the total administered dose (Bard et al., 
2000) (DeMattos et al., 2002) (Banks et al., 2005).  However, even these low 
levels of antibody are sufficient to elicit a profound reduction in pathology. After 
anti-Aß antibodies cross the blood brain barrier, there were two suggested 
mechanisms of action for the removal of amyloid deposits.  The first involves the 
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catalytic disaggregation of Aß fibrils or neutralization of Aß oligomers leading to 
clearance from the brain (Solomon et al., 1997) (Klyubin et al., 2005). The 
second mechanism relates to microglial-mediated phagocytosis or degradation of 
Aß by activated microglia.   
The constant region (Fc) on the anti-Aß antibody activates microglia via 
the Fcγ-receptor. Fcγ-activation stimulates microglial-mediated phagocytosis of 
Aß (Schenk et al., 1999) (Bard et al., 2000) (Wilcock et al., 2004a). The studies 
conducted by Wilcock and colleagues with monoclonal anti-Aß antibodies have 
led us to conclude that the removal of fibrillar Aß deposits in the APP transgenic 
mice is facilitated when microglial cells are activated. First, the time course of 
Congo red clearance following intracranial injections of anti-Aß antibodies 
coincides with elevation of CD45 expression in microglia (Wilcock et al., 2003). 
Second, co administration of dexamethasone with intracranial injections of intact 
IgG or Fab2 fragments results in the prevention of microglia activation, and the 
clearance of fibrillar Aß deposits is blocked (Wilcock et al., 2004a). Thirdly, a time 
course of passively administered antibodies in Tg2576 mice compared the 
effects of 1, 2 or 3 months of treatment on histopathology and behavior in 
Tg2576 mice. The results showed a complex microglial response that correlated 
with amyloid reductions and cognitive improvements (Wilcock et al., 2004b). In 
addition to the evidence of microglial involvement in Aß clearance in APP mice, 
neuropathological investigations of 3 patients immunized with AN-1792 showed 
less than expected Aß pathology in focal regions of the brain with remaining 
microglia filled with Aß (Masliah et al., 2005) (Nicoll et al., 2003).  
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More recently, microglial activation has been shown surrounding amyloid-
containing blood vessels following systemic immunization. Aß deposition in the 
cerebral vasculature is a condition referred to as cerebral amyloid angiopathy 
(CAA). Severe CAA disrupts the integrity of the blood vessels and amplifies the 
potential for microhemorrhages.   In a three month passive immunization time 
course study with old Tg2576 mice and a C-terminal anti-Aß antibody, Wilcock 
and colleagues demonstrated an antibody-exposure-time-dependent increase in 
vascular deposition with a concommitant decrease in parenchymal Aß levels 
(Wilcock et al., 2004b). CD45 immunohistochemistry showed that these amyloid-
burdened blood vessels were affiliated with increased microglial activation 
(Wilcock et al., 2004b). Furthermore, a study with APP23 transgenic mice, a 
model with parenchymal and significant vascular Aß deposition, showed that the 
incidence and severity of microhemorrhage increased more than twofold after 6 
weeks of passive immunization with an N-terminal anti-Aß antibody (Pfeifer et al., 
2002). Similar to the results obtained by Pfeifer et al. (2002),  increased 
incidence of CAA and microhemorrhage were also observed in aged PDAPP 
mice treated for 6 weeks with an N-terminal anti-Aß antibody (Racke et al., 
2005). An important question following these observations is what mechanism 
caused the antibodies to exacerbate the CAA-associated microhemorrhage? The 
microglial association with amyloid-burdened blood vessels suggests that 
antibody-mediated microglial activation via the Fc receptor may play a dominant 
role.  
To answer this question, we have tested a deglycosylated C-terminal anti-
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Aß antibody. The deglycosylation of carbohydrate side chains on the Fc portion 
of an anti-Aß antibody greatly reduces the affinity of the antibody for Fcγ 
receptors, particularly murine FcγRIIb and FcγRIIIa, on effector cells like 
microglia; yet deglycosylated antibodies are fully capable of binding to Aß with an 
identical affinity as the intact antibody (Ravetch, 1997) (Gessner et al., 1998). 
The deglycosylated antibody offers a unique ability to ascertain which features of 
the microglial reaction to antibody administration are caused by opsonized 
antigen binding to the effector molecules, by comparison to mice injected with 
intact antibodies. Immunohistochemical analyses of APP brain sections after 
intracranial injections of intact or deglycosylated antibody confirmed that 
deglycosylation does not activate microglia to the same extent when compared to 
mice treated with control or native intact anti-Aß IgG as measured with antibodies 
against FcγRII/III and CD45 (Carty et al., 2006). Furthermore, deglycosylation of 
the Fc portion on the anti-Aß antibody significantly reduces the severity of CAA 
and microhemorrhage compared to native antibodies when passively 
administered to Tg2576 mice, albeit with slightly lower clearance of parenchymal 
amyloid deposits (Wilcock et al., 2006). One explanation for our prior results is 
that by deglycosylating the Aß antibody, we are able to mitigate specific 
antibody-mediated mechanisms that contribute to the accumulation of CAA and 
microhemorrhage.   
Alternatively, we suggest that the deglycosylated antibody may remove Aß 
from the brain at a slower rate, resulting in less saturation of vascular efflux 
pathways and minimized accumulation of vascular deposits.  One means of 
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resolving the qualitative (specific mechanism) versus quantitative (slower 
removal) explanations of the effects of antibody deglycosylation on vascular 
amyloid accumulation would be to increase the rate of amyloid removal with 
higher doses of deglycosylated antibodies. If a higher rate of amyloid removal by 
deglycosylated antibody increased vascular deposits like native antibodies, then 
the quantitative explanation would be most likely.  
Here we examined the rate of Aß clearance from the brain and its effect 
on CAA and microhemorrhage by passively administering 3 doses of 
deglycosylated anti-Aß antibody in old Tg2576 mice for 3 months in paper 1. We 
chose the 3 month treatment regimen because previous studies have shown 
significant reductions in parenchymal amyloid at this time point as well as 
increased CAA and microhemorrhage (Wilcock et al., 2004b).  Based on prior 
studies which validate that 0.1% of peripherally administered antibody enters the 
CNS, we designed a dose response study using the deglycosylated Aß antibody 
with the notion that higher doses of peripherally administered antibody would 
enter the brain and clear amyloid at a higher rate, while the smaller doses would 
clear amyloid at the slower rates (Banks et al., 2002) (Bard et al., 2000). 
Somewhat paradoxically, we found that long term systemic administration of low 
doses of deglycosylated anti-Aß are more effective at reducing amyloid deposits 
and reversing cognitive deficits in old APP transgenic mice when compared to 
animals treated with intermediate or higher doses of antibody (Paper 1). 
Interestingly, all groups had similar increases in CAA despite the differences in 
plaque clearance (Paper 1; Figure 5 & 6C). The number of microhemorrhages 
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was less than one profile per section for all groups, considerably less than that 
found in prior studies with intact antibody (Paper 1; Figure 7). A possible 
explanation for the inverse dose response may be that excess antibody unbound 
to antigen can interfere with antibody-mediated Aß clearance, possibly by 
saturating the FcRn antibody transporter. 
 It is well known that the LRP receptor mediates the efflux of Aß from the 
brain and that RAGE mediates the influx of Aß across the blood brain barrier 
(BBB) (Deane et al., 2003) (Deane et al., 2004a). More recently, FcRn 
expression was found at the brain microvasculature and choroid plexus 
epithelium on the BBB (Lazarov et al., 2005) and may mediate the 'reverse 
transcytosis' of IgG and immune complexes from the brain to blood direction 
(Schlachetzki et al., 2002). Deglycosylation of antibodies does not change the 
interaction of immunoglobin with the FcRn (Hobbs et al., 1992).  Previous studies 
have shown that receptor mediated Aß efflux mechanisms can become saturated 
with high levels Fc fragments or intact IgG but not by high concentrations of Fab2 
fragments or albumin (Zhang and Pardridge, 2001). Furthermore, the FcRn 
transport system was found to be the main mechanism mediating the 
transcytosis of Aß-anti-Aß immune complexes from the brain to blood in old 
Tg2576 mice (Deane et al., 2005). This group also found that antibody-mediated 
Aß clearance from the brain is abolished in old FcRn -/- mice (Deane et al., 
2004b). Similar to Zhang and Pardridge, Deane and colleagues demonstrated 
that the addition of excess IgG inhibited the clearance of immune complexes 
from the brain. Therefore, high concentrations of immunoglobin will saturate the 
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FcRn receptors with antibody not bound to antigen, hinder the FcRn binding of 
Aß-anti-Aß immune complexes, and ultimately result in the inhibition of Aß 
clearance from the brain.  The saturation of FcRn may explain why high doses of 
deglycosylated antibody are not as effective at reducing diffuse and fibrillar Aß 
compared to antibodies administered at lower doses.  The saturation of this efflux 
system may also result in the accumulation of Aß along the brain 
microvasculature and lead to the formation of CAA.  
The 3 month time point chosen for the dose response study allowed for us 
to examine changes in the distribution and levels of Aß, cognitive improvements, 
and microhemorrhage.  However, based up the earlier time course study with 
intact anti-Aß antibodies, microglial markers return to baseline at 3 months 
(Wilcock et al., 2004b). In the dose response study, we showed no differences in 
CD45 expression between the 3 doses of deglycosylated antibody and the 
control group at the 3 month time point (Paper 1; Table 1). Even though the 
deglycosylated antibody was designed to avoid activation of the Fcγ receptor, the 
antibody may still elicit changes in microglial expression indirectly. Further 
experimentation is required to examine changes in microglial phenotypes with 
the administration of a deglycosylated anti-Aß antibody in the form of a time 
course study with a similar experimental design as Wilcock et al. (2004a).  
Elucidating the series of changes in the microglial phenotype that occur during 
the active phase of amyloid removal will be useful in identifying features critical to 
clearance of antigen-antibody complexes, and in identifying changes associated 
with the buildup of vascular deposits. 
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In addition to the further experimentation in the form of a time course, 
brain leptomeningeal vessels could be isolated from the mice used in the time 
course study to examine changes in Aß content, vascular markers, as well as 
FcRn expression.  The surface leptomeningeal vessels of the transgenic mouse 
brain provide an ideal system to examine CAA, because vessel segments of up 
to several hundred micrometers in length can be observed (Prada et al., 2007).  
Besides the antibody dose and the subsequent rate of Aß clearance from 
the brain, the epitope that anti-Aß antibodies recognize may be a critical factor in 
parenchymal Aß clearance and redistribution. Intracranial injections of N-
terminal, mid domain, and C-terminal anti-Aß antibodies resulted in similar 
reductions in diffuse and fibrillar Aß as measured with Aß immunohistochemistry 
and thioflavin-S histochemistry, respectively (Wilcock; data not published). 
Several passive immunization studies with N-terminal, mid domain, and C-
terminal antibodies have shown significant reductions in amyloid plaque burden 
(Bard et al., 2003) (DeMattos et al., 2001) (Wilcock et al., 2004b).  Independent 
studies have demonstrated increased CAA and microhemorrhage following 
passive administration of N- and C-terminal antibodies (Wilcock et al., 2006) 
(Pfeifer et al., 2002) (Racke et al., 2005). 
In order to determine if increased vascular amyloid and hemorrhage are 
conditions that result from epitope specificity, we directly compared aged Tg2576 
mice passively immunized with antibodies directed against the N-terminal of Aß1-
5, the mid domain of Aß16-28, or the C-terminal of Aß33-40.  After 3 months of weekly 
intraperitoneal injections, the mice were tested in a radial arm water maze 
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paradigm for learning and memory.  The behavioral test revealed cognitive 
improvements in mice treated with the N-terminal and C-terminal anti-Aß 
antibodies as compared to mice treated with control IgG, while the mice treated 
with mid domain antibody failed to show behavioral improvements (Paper 2; 
Figure 1). Despite the differences found with the behavioral data, all three 
antibodies resulted in similar reductions of diffuse Aß (Paper 2; Figures 2 & 3). 
However, only the N- and C-terminal antibodies were able to significantly reduce 
fibrillar Aß as measured with Congo red histochemistry (Paper 2; Figures 4 & 5). 
Interestingly, of the 3 antibodies tested, the C-terminal antibody caused the 
greatest reductions in Aß with more than 90% of the parenchymal deposits 
removed (Paper 2; Figure 5B). These reductions were associated with increases 
in vascular Aß (Paper 2; Figure 5C).    
Another significant observation from this experiment was that behavioral 
improvements correlated with reductions in compact amyloid, which suggests 
that compact amyloid plaques contain a species of Aß that is critical for 
acquisition of memory. Both the N- and C-terminal antibody resulted in significant 
incidences of microhemorrhage (Paper 2; Figure 6). We did not observe 
substantial Aß clearance with dramatically less vascular amyloid accumulation 
with one particular antibody. These data suggest that the degree of parenchymal 
Aß clearance determines the extent of vascular Aß accumulation and 
hemorrhage development; epitope specificity is not critical in directing the 
vascular accumulation. 
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The mechanism by which anti-Aß antibody therapy results in increased 
CAA remains unclear. One hypothesis is that the microglia are capable of 
phagocytosing the amyloid plaques but are unable to degrade them so they 
transport the amyloid to the vessels where they dispose of it into the vessel wall. 
Support for this hypothesis comes from CD45 immunohistochemistry which 
showed that, despite overall microglial activation being reduced to control levels 
following three months of anti-Aß antibody treatment, there appeared to be high 
levels of microglial activation around those vessels containing amyloid (Wilcock 
et al., 2004b).  Deglycosylated antibodies further support this contention, as the 
severity of CAA and occurrence of microhemorrhage are significantly mitigated 
when Fcγ receptor activation is abated (Carty et al., 2006) (Wilcock et al., 2006) 
(Paper 1).  
A second hypothesis for increased CAA after immunization is that the 
antibody binds to Aß already present in the vasculature. In vitro and in vivo 
binding assays showed that N-terminal but not mid-domain anti-Aß antibodies 
directly bind to Aß in the vessels (Racke et al., 2005). The formation of this 
immune complex results in a local inflammatory reaction, which might destabilize 
the already weakened vessel (Pfeifer et al., 2002) (Burbach et al., 2007). It is 
also plausible that receptor-mediated Aß clearance mechanisms become 
saturated or overwhelmed with increased mAb:Aß immune complexes, increased 
free antibody, or increased soluble Aß in the brain following administration of 
anti-Aß antibodies.    
 117
In sporadic AD, as well as in Tg2576 mice, vascular amyloid is mainly 
composed of Aß1-40 with a lesser, variable amount of Aß1-42 (Kawarabayashi 
et al., 2001). In sporadic AD, leptomeningeal amyloid exhibits minimal 
modifications while parenchymal plaques commonly exhibit  N-terminal 
degradations and posttranslation modifications (Roher et al., 1993) (Kuo et al., 
1997).  Interestingly, the composition of vascular amyloid observed in the 
patients vaccinated with AN 1792 resembled that of the typical AD parenchymal 
amyloid plaque with N-terminal and chemical modifications (Patton et al., 2006). 
These observations further suggest a mobilization of Aß from the parenchyma to 
the vasculature with immunization. Additionally, vascular Aß1-42 was elevated in 
the individuals vaccinated with AN 1792 compared to nonimmunized AD controls 
(Nicoll et al., 2006).   
Comprehending the ultimate effects of plaque amyloid dispersal on brain 
vascular function is vital.  Parenchymal Aß may exert deleterious effects on 
vascular endothelial and smooth muscle cell metabolism. Soluble Aß is a potent 
vasoconstrictor capable of altering cerebral blood flow, (Thomas et al., 1996) and 
Aß peptides are also powerful angiogenesis inhibitors (Paris et al., 2004). 
Changes in vascular Aß content have not been closely examined in APP 
transgenic mice following immunization with anti-Aß antibodies.  
Several important questions can be tested using anti-Aß antibodies such 
as: what factor/s influence the deposition of Aß? What happens after 
immunotherapy is stopped?  Is Aß deposition a factor of time or age? In order to 
answer such questions, we first proposed two hypotheses regarding the 
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deposition of Aß.  One hypothesis assumes that Aß deposition is a result of 
production exceeding clearance mechanisms by a small amount, and the excess 
becomes converted to a form that deposits and builds up in a time dependent 
manner (Maggio et al., 1992) (Prior et al., 1996). This statement describes the 
accumulation hypothesis (Paper 3; Figure 1A). The other hypothesis suggests 
that the rate of Aß production, degradation and removal is altered with age, and 
was termed the equilibrium hypothesis (Paper 3; Figure 1B).   
We tested these hypotheses by delaying Aß deposition in Tg2576 mice 
using passive immunization with a C-terminal anti-Aß antibody starting at an age 
when amyloid deposition first begins (8 months) and ending treatment 6 months 
later at an age when control Tg2576 mice have considerable amounts of 
deposited amyloid. In order to evaluate the pattern of amyloid deposition, we 
allowed 3 months post-treatment for amyloid to deposit in these mice.  
 The variables measured in this experiment were total Aß, which consists 
of diffuse and compact amyloid, Congo red positive compact amyloid, and 
markers of microglial activation. The percent areas of each of these variables 
were plotted on a line graph to reveal a pattern of deposition that resembled the 
theoretical graph for the accumulation hypothesis (Paper 3; Figures 2, 3, & 4). 
Following successful suppression of Aß deposition with anti-Aß immunotherapy, 
cessation of treatment resulted in delayed diffuse and compact Aß accumulation.  
The deposition of amyloid never reached the levels found in Tg2576 mice treated 
with control IgG.   The control transgenic mice displayed accelerated increases in 
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both diffuse and compact amyloid pathology, as well as microglial expression 
between the 14 and 17 month data points (Paper 3; Figures 2, 3, & 4).   
We also examined individual changes in Aß40 and Aß42 with ELISAs and 
confirmed the trends found with the histological markers.  Significant reductions 
were found in the levels of both Aß40 and Aß42 in the transgenic mice treated 
with 2H6 at the 14 month time point (Paper 3; Figures 5A & B). These significant 
reductions were maintained 3 months after treatment was stopped. Interestingly, 
the 2H6 antibody directed against Aß33-40 was able to reduce Aß42.  
The results from this study have provided us with the information to 
suggest that Aß accumulates as a function of time. Aß accumulation in a time-
dependent manner results in amyloid plaques that are less malleable, and active 
clearance of Aß may be necessary to remove existing plaques.  The 
accumulation hypothesis indicates that treatments which reduce Aß production or 
increase soluble Aß clearance might prevent further Aß deposition, but would not 
remove existing deposits. We interpret our findings as evidence that AD 
therapies that alter the production of Aß by inhibiting secretase activity or 
inhibiting APP expression may not quickly reverse preexisting pathology. These 
data strongly support the use of prophylactic treatments, as it appears that 
amyloid deposits will require interventions that actively clear amyloid as the only 
means to efficiently reduce brain Aß in AD.   
To further explain the pattern of amyloid accumulation following 
immunization, we assume that the administration of anti-Aß mAbs, before the 
deposition of amyloid, altered some select pool or species of Aß that was present 
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at low abundance and critical for deposition. It is critical that biochemical 
analysis, on the remaining tissue from the accumulation study, be performed to 
determine changes in forms of Aß that act as seeds and drive Aß accumulation.  
We have found that cognitive improvements in aged Tg2576 mice 
accompany reductions in compact amyloid plaques after chronic administration 
of anti-Aß antibodies (Paper 1 & 2). In support of these findings, active 
immunization with Aß of double mutant APP TgCRND8 mice partially prevented 
the development of reference memory deficits in a water maze task, with only a 
50% reduction in the size and number of dense core amyloid deposits, and no 
effect on the total soluble pool of Aß in brain (Janus et al., 2000). The 
researchers concluded that the prevention of memory deficits was due to the 
reduced amyloid pathology seen in their immunized mice. However, compact 
deposits are likely to be surrounded by a number of smaller, more diffusible, 
oligomeric assemblies. Chronic active immunization had similar beneficial effects 
on memory impairment in two different strains of transgenic mice as assessed 
using a radial-arm water maze (Morgan et al., 2000). Notably, treatment did not 
affect amyloid pathology in the same way in the two strains of mice. Immunized 
APP+PS1 double transgenic mice showed a reduction in diffuse (nonfibrillar) Aß 
deposits in the cerebral cortex and hippocampus, but not in amyloid (fibrillar Aß) 
deposits. In contrast, Tg2576 APP transgenic mice showed a small but 
statistically significant reduction in cortical amyloid burden, suggesting that active 
immunization reduces the development of fibrillar Aß deposits in this mouse 
strain. These authors concluded that active immunization prevents memory 
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deficits by altering either brain amyloid pathology or an unknown pool of non-
deposited Aß, perhaps a soluble pool of Aß. Taken together with our data, these 
results suggest that anti-Aß immunotherapy is able to remove the Aß moiety that 
is responsible for cognitive decline. However, the relationship between soluble 
and insoluble brain Aß concentrations and memory impairment in transgenic 
mice is complex. Further examination into the redistribution and reduction of 
different forms of Aß will be useful to elucidate what form/s of Aß accompanies 
the changes in memory performance in APP transgenic mice following passive 
immunization. 
Research on AD seeks to answer the central question: what causes the 
impairment of episodic memory? It was widely believed that the fibrillar Aß 
peptide found in neuritic plaques was the neurotoxic species and caused the 
neurodegeneration which accompanies the disease.  However, many apparently 
healthy older humans have substantial amounts of amyloid in their cerebrum at 
post-mortem examination, yet do not show the signs and symptoms of AD. 
Furthermore, there are reports of weak quantitative correlations between amyloid 
plaque counts in post-mortem brain sections and the extent of cognitive 
symptoms measured pre-mortem (Katzman, 1986).  There is also evidence that 
APP transgenic mice show memory impairment before the first signs of amyloid 
deposition (Moechars et al., 1999). It has even been postulated that the large Aß 
aggregates play a neuroprotective role by sequestering neurotoxic Aß forms, 
although they are surrounded by dystrophic neurites. However, insoluble protein 
aggregates are likely to be surrounded by a number of smaller, more diffusible 
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assemblies. Therefore, the toxic moiety responsible for synaptic dysfunction and 
neuronal cell loss still remains to be identified.  Currently, the focus has shifted 
from fibrillar Aß as the neurotoxic species to soluble Aß oligomers for their 
subsequent ability to cause neuronal injury.   
A large and confusing body of literature describes many types of assembly 
forms of synthetic Aß, including protofibrils (PFs), Aß-derived diffusible ligands 
(ADDLs), and many lengths of oligomeric Aß.  Protofibrils are intermediates of 
synthetic Aß fibrillization that can continue to polymerize to form amyloid fibrils 
and have a ß-sheet structure.  They are detected with Congo red or thioflavin-S 
(Harper et al., 1997) (Walsh et al., 1997).  ELISAs have shown that soluble 
oligomers correlate much better with the presence and degree of cognitive 
deficits than do plaque counts (Naslund et al., 2000). Small oligomeric species 
that might affect neural signal-transduction pathways have been designated as 
ADDLs (Gong et al., 2003).   Lesne and colleagues searched for the appearance 
of an Aß species that coincided with the first observed changes in spatial 
memory in Tg2576 mice (Lesne et al., 2006).  They found that levels of only 
nonamer and dodecamer forms of Aß correlated with impairment of spatial 
memory.  The purified dodecamer assembly (Aß*56) was injected into the 
ventricle of pre-trained, wild-type rats and caused a dramatic debilitation in 
spatial memory performance (Lesne et al., 2006).  Although levels of Aß*56 
coincide with spatial memory deficits, several studies have shown impaired 
performance in hippocampal-dependent fear conditioning and long-term 
potentiation (LTP) in Tg2576 mice, at ages long before the detection of the 
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dodecamer species (Dineley et al., 2002).   Therefore, at the current stage of 
research, one should not conclude that either large, insoluble deposits or small, 
soluble oligomers represent the sole neurotoxic entity. However, current 
evidence points to the detrimental role of diffusible oligomers in the early, pre-
symptomatic stages of AD.  
 Numerous strategies to prevent Aß aggregation and accumulation are 
being evaluated as ways to treat or prevent AD. Compounds that decrease the 
production of soluble Aß monomers and potentially inhibit the formation of 
soluble oligomers, are the ß or γ- secretase inhibitors. Eli Lilly and Company is 
involved in Phase II trials testing the γ-secretase inhibitor, LY450139 dihydrate.  
This compound has been found to reduce the rate of formation of Aß in vitro and 
in vivo (Siemers et al., 2006). Wyeth Research is testing another γ-secretase 
inhibitor that has previously been shown to reverse cognitive deficits in Tg2576 
mice (Comery et al., 2005). Unfortunately, secretases are expressed 
ubiquitously, and process many important substrates which when inhibited, may 
result in adverse effects.  In addition, recent evidence implies that existing 
plaques are not pliable and may require an active means of clearance. 
Therefore, the inhibition of monomeric Aß production may not be sufficient to 
reverse the disease process (Paper 3) (Jankowsky et al., 2005). 
 Because passive administration of monoclonal anti-Aß antibodies works 
as effectively as active immunization in APP mice, it is generally acknowledged 
that it is the anti-Aß antibody response that mediates the effects of active 
immunization. In contrast to the data discussed above, several studies show 
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reductions in amyloid levels as well as cognitive improvements without the direct 
target of Aß.  In an AD patient with stroke, Akiyama and McGeer (2004) 
observed local reductions in senile plaques in cortical areas affected by ischemia 
and suggested that the observed reductions in Aß were a result of an 
inflammatory response. Furthermore, this group proposed that the effects of anti-
Aß immunotherapy may be more related to nonspecific immune activation than to 
actions directed against the Aß peptide (Akiyama and McGeer, 2004). A series of 
agents that cause general immune activation, often including T cells, have been 
found to reduce amyloid loads. These include Borna virus infection (Stahl et al., 
2006), glatiramer acetate (Butovsky et al., 2006) and a proteosome adjuvant 
(Monsonego et al., 2006). Nasal vaccination with a proteosome-based adjuvant 
alone and in combination with glatiramer acetate decreased Aß plaques in an 
APP transgenic mouse model (Frenkel et al., 2005). The clearance was 
demonstrated in B-cell deficient mice and in mice with an intact immune system.  
The suggested mechanism of action was antibody-independent and involved the 
induction of T cells and activation of microglia (Frenkel et al., 2005).  Tg2576 
mice inoculated with the Borna virus showed a persisting, subclinical infection of 
cortical and limbic brain areas characterized by slight T-cell infiltrates, expression 
of cytokines, and massive microglial activation in the hippocampus and 
neocortex (Stahl et al., 2006). Interestingly, Stahl and colleagues revealed a 
decrease in thioflavin-S positive plaques companied with increased CAA 
following infection with the borna virus (Stahl et al., 2006). 
 125
Overall, we have shown evidence that Aß accumulates in a time-
dependent manner.  As a result, active clearance methods are required to 
successfully reverse existing pathology.  Moreover, it is important to emphasize 
the requirement for precise titration of dose-response characteristics because 
saturation of influx and efflux mechanisms may play a major role in the efficacy of 
Aß clearance. We also show that epitope specificity is not critical in directing 
vascular Aß accumulation but the degree of parenchymal Aß clearance 
determines the extent of vascular Aß accumulation and hemorrhage 
development. A great deal of experimentation is still required in order to elucidate 
why CAA is exacerbated following immunization.  
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APPENDIX A: BINDING AFFINITIES OF IgG ISOTYPES TO FC-GAMMA 
RECEPTORS 
 
 
Biological and pathological activities differ with various IgG isotypes. 
These differences have conventionally been attributed to disparities in the ability 
of certain isotypes to engage complement or one of the known FcγR.  The 
finding that individual FcγRs interact differently with IgG isotypes in mediated 
protective inflammatory responses is certainly relevant for the potential use of 
these receptors as therapeutic targets in the treatment of disease.  Murine 
effector cells such as microglia within the CNS express four different classes of 
IgG-specific Fc receptors: a high affinity receptor, FcγRI, two low affinity 
receptors, FcγRII and FcγRIII, and an intermediate affinity receptor, FcγRIV 
(Ravetch, 1997) (Nimmerjahn et al., 2005).  Fcγ receptors I, III, and IV are all 
activating receptors characterized by an immunoreceptor tyrosine-based 
activation motif (ITAM).  These receptors are important for triggering 
phagocytosis by activated macrophages.  FcγRII is an inhibitory receptor 
characterized by the presence of an ITIM motif that recruits inhibitory 
phosphatases that limit effective signaling.  Table 1 is a summary of previously 
published affinities of different isotypes of IgG for the various Fcγ receptors.   
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Table 1 
Affinities (Kd) of antibody isotype for Murine Fcγ receptors   
Isotype mFcγRI (M) mFcγRIIb (M) mFcγRIII (M) mFcγRIV (M) 
IgG1 X 3.01 x 10-7 
 
3.2 x 10-6 
 
X 
IgG2a 1 x 10-9 2.39 x 10-6 
 
1.46 x 10-6 
 
3.45 x 10-8 
 
IgG2b X 4.48 x 10-7          1.55 x 10-6         5.9 x 10-8  
X indicates no detectable binding 
 
Binding affinity of 2H6 and D-2H6 antibodies to Fcγ receptors or 
complement protein C1q were measured using BIAcore (table 2). Purified murine 
Fcγ receptors (from R&D Systems) and human C1q (from Quidel) were 
immobilized on BIAcore CM5 chip by amine chemistry: Fcγ receptors or C1q 
were diluted into 10 mM sodium acetate pH 4.0 and injected over an EDC/NHS 
activated chip at a concentration of 0.005 mg/mL. Variable flow time across the 
individual chip channels were used to obtain 2000–3000 response units (RU). 
The chip was blocked with ethanolamine. Serial dilutions of monoclonal 
antibodies (ranging from 2 nM to 70 μm) were injected. HBS-EP (0.01 M HEPES, 
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20) was used as running 
and sample buffer. Regeneration studies showed that a mixture of Pierce elution 
buffer (Product No. 21004, Pierce Biotechnology, Rockford, IL) and 4 M NaCl 
(2:1) effectively removed the bound antibody peptide while keeping the activity of 
Fcγ receptors and C1q. Binding affinities of Aß for the antibodies was determined 
similarly by immobilizing the antibodies on a CM5 chip using amine chemistry, 
and flowing AB1-40 over the chip at multiple concentrations. Binding data were 
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analyzed using 1:1 Langmuir interaction model for high affinity interactions, or 
steady state affinity model for low affinity interactions (Carty et al., 2006). 
Table 2 
Affinities (Kd) of 2H6, De-2H6, and 2286  for effector proteins 
Antibody Isotype mFcγRI (nM) mFcγRIIb (nM) mFcγRIII (μM) hC1q (μM) 
2H6 IgG2b 1,600 20,000 39,000   5,000 
De-2H6 IgG2b 6,500 30,000 67,000 30,000 
2286 IgG1 87 2,000 1,000 >100,000 
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